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Understanding the trends in the prevalence of cigarette 
smoking among youths enables policy makers to target preven-
tion resources more effectively. Every 2 years, CDC analyzes 
data from the national Youth Risk Behavior Survey (YRBS) to 
evaluate trends in cigarette use among high school students in 
the United States. This report updates a previous report (1) and 
describes results of CDC’s 2010 analysis of YRBS data from 
1991–2009 for three measures: ever smoked cigarettes, cur-
rent cigarette use, and current frequent cigarette use. For ever 
smoked cigarettes, the prevalence did not change from 1991 
(70.1%) to 1999 (70.4%), declined to 58.4% in 2003, and 
then declined more gradually, to 46.3% in 2009. For current 
cigarette use, the prevalence increased from 27.5% in 1991 to 
36.4% in 1997, declined to 21.9% in 2003, and then declined 
more gradually, to 19.5% in 2009. For current frequent cigarette 
use, the prevalence increased from 12.7% in 1991 to 16.8% 
in 1999, declined to 9.7% in 2003, and then declined more 
gradually, to 7.3% in 2009. For all three measures, rates began 
to decline in the late 1990s, but the rate of decline slowed dur-
ing 2003–2009. To increase the rate of decline in cigarette use 
among high school students, reductions in advertising, promo-
tions, and commercial availability of tobacco products should 
be combined with full implementation of communitywide, 
comprehensive tobacco control programs (2–5).
The biennial national YRBS, a component of CDC’s Youth 
Risk Behavior Surveillance System, used independent, three-
stage cluster samples for the 1991–2009 surveys to obtain 
cross-sectional data representative of public and private school 
students in grades 9–12 in all 50 states and the District of 
Columbia.* For each survey, students completed anonymous, 
self-administered questionnaires that included identically 
worded questions about cigarette use. During 1991–2009, the 
number of participating schools ranged from 110 to 159, and 
the number of participating students ranged from 10,904 to 
16,410. School response rates ranged from 70% to 81%, stu-
dent response rates ranged from 83% to 90%, and the overall 
response rates ranged from 60% to 71%.
For this analysis, ever smoked cigarettes was defined as ever 
trying cigarette smoking, even one or two puffs; current cigarette 
use was defined as smoking cigarettes on at least 1 day during 
the 30 days before the survey; and current frequent cigarette use 
was defined as smoking cigarettes on 20 or more days during 
the 30 days before the survey. Race/ethnicity data were analyzed 
only for non-Hispanic black, non-Hispanic white, and Hispanic 
students (who might be of any race); the numbers of students 
from other racial/ethnic groups were too small for meaningful 
analysis. Data were weighted to provide national estimates, and 
the statistical software used for all data analyses accounted for 
the complex sample design. Temporal changes were analyzed 
using logistic regression analyses, which controlled for sex, 
race/ethnicity, and grade and simultaneously assessed linear, 
quadratic, and cubic time effects (p<0.05).†
Significant linear, quadratic, and cubic effects were detected 
for all three measures (Table 1 and Figure 1). The percentage 
of students who ever smoked cigarettes did not change from 
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cigarette use increased from 1991 to 1999, declined 
from 1999 to 2003, and then remained stable. Among 
black female students, only linear and quadratic effects 
were observed, indicating that the prevalence of cur-
rent cigarette use increased from 1991 to 1999 and 
then declined, with no slowing or leveling off.
Reported by
Office on Smoking and Health, Div of Adolescent and 
School Health, National Center for Chronic Disease 
Prevention and Health Promotion, CDC.
Editorial Note
The findings in this report show that for three 
measures of cigarette use (ever smoked cigarettes, cur-
rent cigarette use, and current frequent cigarette use), 
rates among high school students began to decline in 
the late 1990s, but the rate of decline slowed during 
2003–2009. These trends are consistent with trends 
for 30-day and daily cigarette use reported from the 
Monitoring the Future survey (an ongoing national 
study of the behaviors, attitudes, and values of 8th-, 
10th- , and 12th-grade students), which also showed 
declines starting in the late 1990s but gradual declines 
most recently (6). As a result of the slow declines in 
youth smoking described in this report, the Healthy 
1991 (70.1%) to 1999 (70.4%), declined to 58.4% 
in 2003, and then declined more gradually to 46.3% 
in 2009. The percentage of students who reported 
current cigarette use increased from 27.5% in 1991 
to 36.4% in 1997, declined to 21.9% in 2003, and 
declined more gradually to 19.5% in 2009. The per-
centage of students who reported current frequent 
cigarette use increased from 12.7% in 1991 to 16.8% 
in 1999, declined to 9.7% in 2003, and then declined 
more gradually to 7.3% in 2009.
For current cigarette use, trend analyses were 
conducted by sex, race/ethnicity, and grade in school 
(Figures 2 and 3). Significant linear, quadratic, and 
cubic effects similar to the overall analysis were 
observed for current cigarette use among female stu-
dents overall, white female students, black students 
overall, black male students, 9th-grade students, and 
10th-grade students (Table 2). Among male students 
overall, white students overall, white male students, 
Hispanic male students, and 11th-grade students, 
current cigarette use increased from 1991 to 1997, 
declined from 1997 to 2003, and then remained 
stable. Among Hispanic students overall and Hispanic 
female students, current cigarette use increased from 
1991 to 1995, declined from 1995 to 2003, and then 
remained stable. Among 12th-grade students, current 
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free environments, programs that promote changes in 
social norms, and comprehensive communitywide and 
school-based tobacco-use prevention policies)(2–5).
The findings in this report are subject to at least 
two limitations. First, these data apply only to youths 
who attend school and, therefore, are not representa-
tive of all persons in this age group. Nationwide, in 
2007, of persons aged 16–17 years, approximately 4% 
were not enrolled in a high school program and had 
not completed high school (9). Second, the extent 
of underreporting or overreporting of cigarette use 
cannot be determined, although the survey questions 
demonstrate good test-retest reliability (10).
People 2010 national health objective to reduce the 
prevalence of current cigarette use among high school 
students to ≤16%§ has not been met.
The findings in this report also show that since 
2003 the rate of decline in current cigarette use slowed 
or leveled off for all racial/ethnic and sex subgroups 
except black female students, for which no slowing 
or leveling off occurred in the rate of decline after 
1999. Cigarette smoking rates reflect complex and 
interrelated individual, social, and environmental 
factors (4,7). More detailed research is needed to 
explain why current cigarette use during 2003–2009 
declined more slowly among some racial/ethnic and 
sex subgroups of high school students but remained 
stable among others.
The impact of tobacco advertising and promo-
tion activities on youth smoking initiation has been 
documented previously (8). The increase in current 
cigarette use among high school students during the 
early to mid-1990s observed in this and other surveys 
might have resulted from expanded tobacco company 
promotional efforts, including discounted prices on 
cigarette brands most often smoked by adolescents, 
depictions of tobacco use in movies, distribution of 
nontobacco products with company symbols (e.g., 
hats and T-shirts), and sponsorship of music concerts 
and other youth-focused events (7). Reductions in 
advertising, promotions, and commercial availabil-
ity of tobacco products should be combined with 
expanded counter-advertising mass media campaigns 
and implemented with other well-documented and 
effective strategies (e.g., higher prices for tobacco 
products through increases in excise taxes, tobacco-
TABLE 1. Percentage of high school students who had ever smoked cigarettes,* were current cigarette users,† and were current frequent 
cigarette users§ — Youth Risk Behavior Survey, United States, 1991–2009¶
Category

















































































 * Ever tried cigarette smoking, even one or two puffs.
 † Smoked cigarettes on at least 1 day during the 30 days before the survey.
 § Smoked cigarettes on 20 or more days during the 30 days before the survey.
 ¶ Linear, quadratic, and cubic trend analyses were conducted using a logistic regression model controlling for sex, race/ethnicity, and grade. 
 ** Confidence interval.
 †† Significant linear, quadratic, and cubic effects were detected (p<0.05).
* Ever tried cigarette smoking, even one or two puffs.
† Smoked cigarettes on at least 1 day during the 30 days before the survey.
§ Smoked cigarettes on 20 or more days during the 30 days before the survey.
FIGURE 1. Percentage of high school students who had ever smoked cigarettes,* 
were current cigarette users,† and were current frequent cigarette users§ — 
Youth Risk Behavior Survey, United States, 1991–2009
Ever smoked cigarettes
Current cigarette use

















§ Additional information available at http://www.healthypeople.gov/
document/pdf/volume2/27tobacco.pdf.
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The Family Smoking Prevention and Tobacco 
Control Act (Tobacco Control Act),¶ enacted in 2009, 
provides new opportunities for broad scale reductions 
in tobacco use. This statute gives the Food and Drug 
Administration (FDA) additional authority to regu-
late the tobacco industry. The Act imposes specific 
marketing, labeling, and advertising requirements, 
and establishes restrictions on youth access and pro-
motional practices that are particularly attractive to 
youth. The provisions of the Act offer opportunities 
for FDA to work as a partner in tobacco prevention 
and control (e.g., through collaborations with CDC 
and other federal and state agencies) (5). As suggested 
by the Institute of Medicine, the regulation of tobacco 
products is an important component of a comprehen-
sive national tobacco prevention and control strategy 
that will complement and strengthen the impact of 
traditional, evidence-based interventions (4).
What is already known on this topic?
National data show that the prevalence of cigarette 
use among youths began to decline in the late 1990s.
What is added by this report?
The findings in this report show that for three mea-
sures of cigarette use (ever smoked cigarettes, current 
cigarette use, and current frequent cigarette use), 
rates among high school students began to decline in 
the late 1990s, but the rate of decline slowed during 
2003–2009.
What are the implications for public health practice?
To reduce the adverse health consequences associ-
ated with tobacco use, the most effective evidence-
based strategies to reduce initiation of tobacco use 
among youths should be implemented nationwide, 
including higher prices for tobacco products, 
tobacco-free environment policies, and counter-
advertising mass media campaigns.
¶ Family Smoking Prevention and Tobacco Control Act, Pub. L. 
No.111-31, 123 Stat 1776 (2009). Additional information available 
at http://www.gpo.gov/fdsys/pkg/PLAW-111publ31/content-detail.
html.
* Smoked cigarettes on at least 1 day during the 30 days before the survey.
FIGURE 3. Percentage of high school students who were current cigarette 
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* Smoked cigarettes on at least 1 day during the 30 days before the survey.
FIGURE 2. Percentage of high school students who were current cigarette 
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 * Smoked cigarettes on at least 1 day during the 30 days before the survey.
 † Linear, quadratic, and cubic trend analyses were conducted using a logistic regression model controlling for sex, race/ethnicity, and grade. 
 § Confidence intervals.
 ¶ Significant linear, quadratic, and cubic effects were detected (p<0.05).
 ** Numbers for other racial/ethnic groups were too small for meaningful analysis.
 †† Significant linear and quadratic effects only were detected (p<0.05).
 7. Nelson DE, Mowery P, Asman K, et al. Long-term trends in 
adolescent and young adult smoking in the United States: 
metapatterns and implications. Am J Public Health 2008;98: 
905–17.
 8. National Cancer Institute. The role of the media in promoting 
and reducing tobacco use. Tobacco control monograph no. 
19. Bethesda, MD: US Department of Health and Human 
Services, National Institutes of Health, National Cancer 
Institute; 2008. Available at http://cancercontrol.cancer.gov/
tcrb/monographs/19/m19_complete.pdf. Accessed July 1, 
2010.
 9. Catalid EF, Laird J, KewalRamani A. High school dropout 
and completion rates in the United States: 2007. Washington, 
DC: US Department of Education, National Center for 
Education Statistics, 2007. Available at http://nces.ed.gov/
pubs2009/2009064.pdf. Accessed  July 1, 2010.
 10. Brener ND, Kann L, McManus T, Kinchen SA, Sundberg 
EC, Ross JG. Reliability of the 1999 Youth Risk Behavior 
Survey questionnaire. J Adolesc Health 2002;31:336–42.
MMWR  Morbidity and Mortality Weekly Report
802 MMWR  /  July 9, 2010  /  Vol. 59  /  No. 26
Nigeria has maintained a high incidence of wild 
poliovirus (WPV) cases attributed to persistently high 
proportions of under- and unimmunized children, 
and, for many years, the country has served as a reser-
voir for substantial international spread (1). In 2008, 
Nigeria reported 798 polio cases, the highest number 
of any country in the world (2). This report provides 
an update on poliovirus epidemiology in Nigeria 
during the past 18 months, January 2009–June 2010, 
and describes activities planned to interrupt transmis-
sion. Reported WPV cases in Nigeria decreased to 
388 during 2009 (24% of global cases), and WPV 
incidence in Nigeria reached an all-time low during 
January–June 2010, with only three reported cases. 
Cases of circulating type 2 vaccine-derived poliovi-
rus (cVDPV2), which first occurred in Nigeria in 
2005 (3), also declined, from 148 during the 12 
months of 2009, to eight during the 6-month period, 
January–June 2010. One indicator of the effectiveness 
of immunization activities is the proportion of chil-
dren with nonpolio acute flaccid paralysis (AFP) who 
never have received oral poliovirus vaccine (OPV). In 
seven high-incidence northern states of Nigeria, this 
proportion declined from 17.6% in 2008 to 10.7% 
in 2009. During 2009–2010, increased engagement 
of traditional, religious, and political leaders has 
improved community acceptance of vaccination 
and implementation of high-quality supplementary 
immunization activities (SIAs). Enhanced surveillance 
for polioviruses, further strengthened implementation 
of SIAs, and immediate immunization responses to 
newly identified WPV and cVDPV2 cases will be 
pivotal in interrupting WPV and cVDPV2 transmis-
sion in Nigeria.
Immunization Activities
Routine immunization against polio in Nigeria 
consists of trivalent OPV (tOPV, types 1, 2, and 3) at 
birth and at ages 6, 10, and 14 weeks. Immunization 
coverage is measured using both administrative data 
(estimated doses administered per targeted child 
population, determined by official census numbers) 
and coverage surveys.  In 2009, using administrative 
data, national routine immunization coverage of chil-
dren by age 12 months with three tOPV doses was 
63% (range by state: 35%–90%) (4). Using coverage 
surveys, the estimated national coverage with three 
tOPV doses at 12–23 months was 39%, but lower 
in the northeast (28.6%) and northwest (24.3%) 
areas of Nigeria, including the seven high-incidence 
northern states (5).*
In addition to routine immunization, Nigeria 
conducts SIAs† for polio eradication using monova-
lent OPV type 1 (mOPV1), monovalent OPV type 
3 (mOPV3), bivalent OPV types 1 and 3 (bOPV), or 
tOPV. Monovalent vaccines are more effective than 
tOPV in providing protection against the correspond-
ing WPV serotype; bOPV is nearly equivalent to 
mOPV and superior to tOPV in producing serocon-
version to WPV1 and WPV3 (6). Three national SIAs 
were conducted in 2009, using mOPV3, mOPV1, 
and tOPV. Five subnational SIAs were conducted in 
2009, each using mOPV1, mOPV3, tOPV, or both 
mOPV1 and mOPV3. During January–June 2010, 
two national SIAs were conducted, one with bOPV 
and one with tOPV; bOPV, mOPV1, and mOPV3 
were used in three subnational SIAs (Figure 1).
Vaccination histories of children with nonpolio 
AFP are used to estimate OPV coverage among 
the population of children aged 6–59 months. The 
proportion of children with nonpolio AFP reported 
to have never received an OPV dose (zero-dose chil-
dren) from the seven high-incidence northern states 
declined from 17.6% in 2008 to 10.7% in 2009 
(range: 0%–17.0%), with the highest proportions 
occurring in Zamfara and Kano states (Table). In con-
trast, the proportion of reported zero-dose children 
was 2.2% in 13 other northern states and 1.8% in 17 
southern states in 2009. The proportion of children 
with nonpolio AFP reported to have received ≥4 OPV 
doses was 37.4% in the seven high-incidence northern 
states and 60.8% for the entire country.
Progress Toward Poliomyelitis Eradication — Nigeria, 
January 2009–June 2010
* For this report, high-incidence northern states are defined as states 
with ≥0.8 confirmed WPV cases per 100,000 population during 
2008. They are Bauchi, Jigawa, Kaduna, Kano, Katsina, Yobe, and 
Zamfara.
† Mass campaigns conducted during a short period (days to weeks) 
during which a dose of OPV is administered to all children aged 
<5 years, regardless of previous vaccination history. Campaigns 
can be conducted nationally or in portions of the country (i.e., 
subnational SIAs).
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AFP Surveillance
AFP surveillance is monitored using World Health 
Organization (WHO) targets for case detection and 
adequate stool specimen collection.§ The national 
annualized nonpolio AFP detection rate among 
children aged <15 years was 8.2 per 100,000 during 
January–March 2009 and 9.0 per 100,000 during 
January–March 2010. Nonpolio AFP detection rates 
meeting the WHO target were achieved in all 37 
Nigerian states during January–December 2009 and 
in all but one state (Plateau) during January–March 
2010.
The WHO adequate stool specimen target was 
reached in all 37 states and in 683 (88%) of 776 local 
government areas (LGAs) during January–December 
2009, and in 36 states and 557 (72%) LGAs during 
 * Mass campaign conducted during a short period (days to weeks) during which a dose of oral poliovirus vaccine (OPV) is administered to all children aged <5 years, 
regardless of previous vaccination history. Campaigns can be conducted nationally or in portions of the country.
 † Trivalent OPV.
 § Monovalent OPV type 1.
 ¶ Monovalent OPV type 3.
 ** Bivalent OPV.
FIGURE 1. Number of laboratory-confirmed cases, by wild poliovirus (WPV) type or circulating vaccine-derived poliovirus type 2 (cVDPV2) and 






Jan Mar May Jul Sep Nov
2007
Jan Mar May Jul Sep Nov
2008


















































































































































§ AFP cases in children aged <15 years and suspected poliomyelitis 
in persons of any age are reported and investigated, with laboratory 
testing, as possible polio. WHO operational targets for countries 
at high risk for poliovirus transmission are a nonpolio AFP rate of 
at least two cases per 100,000 population aged <15 years at each 
subnational level and adequate stool specimen collection for >80% 
of AFP cases (i.e., two specimens collected at least 24 hours apart, 
both within 14 days of paralysis onset, and shipped on ice or frozen 
ice packs to a WHO-accredited laboratory and arriving at the 
laboratory in good condition).
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January–March 2010. The proportion of LGAs 
meeting both surveillance indicators (nonpolio AFP 
detection rate meeting the target and adequate stool 
specimen collection rate) rose from 78% in 2008 to 
86% in 2009.
WPV and cVDPV Incidence
Reported WPV type 1 (WPV1) cases declined from 
67 during January–June 2009 to seven during July–
December 2009, and to one case during January–June 
2010 (provisional data, as of July 5, 2010) (Figure 2). 
Of the 75 WPV1 cases reported during the entire 
18-month period, January 2009–June 2010, seven 
(9%) occurred in the seven high-incidence northern 
states, 33 (44%) in other northern states, and 35 
(47%) in southern states. The number of LGAs with 
WPV1 cases declined from 49 during January–June 
2009 to one during January–June 2010 (Figure 2). 
Reported WPV type 3 (WPV3) cases declined from 
290 during January–June 2009 to 24 during July–
December 2009, and to two during January–June 
2010. Only three cases of WPV have been reported 
during the first 6 months of 2010. Among 316 
WPV3 cases reported from January 2009–June 2010, 
240 (76%) occurred in the high-incidence northern 
states, 75 (24%) in other northern states, and one 
(<1%) in southern states. The number of LGAs with 
WPV3 cases declined from 147 in January–June 2009 
to two during January–June, 2010 (Figure 2). Of 
391 WPV cases reported with onset during January 
2009–June 2010, 270 (69%) occurred in children 
aged <3 years, 266 (68%) were in children reported 
to have received <4 OPV doses, and 66 (17%) were 
in zero-dose children. The number of cVDPV2 cases 
declined from 137 during January–June 2009 to 11 
during July–December 2009, and to eight during 
January–June 2010.
All WPV isolates undergo partial genomic 
sequencing to determine genetic relatedness. Each 1% 
difference between two isolates correlates with approx-
imately 1 year of undetected circulation between the 
specific chains of transmission. Differences greater 
than 1.5% indicate potential quality issues for sur-
veillance. Three of the seven WPV1 isolates from 
July–December 2009 cases and the one WPV1 isolate 
from 2010 exhibited >1.5% divergence from the 
closest predecessor. Similarly, nine of the 24 (38%) 
WPV3 isolates from July–December 2009 and both 
2010 WPV3 exhibited ≥1.5% divergence.
Reported by
National Primary Health Care Development Agency and 
Federal Ministry of Health; Country Office of the World 
Health Organization, Abuja; Poliovirus Laboratory, 
Univ of Ibadan, Ibadan; Poliovirus Laboratory, Univ 
of Maiduguri Teaching Hospital, Maiduguri, Nigeria. 
African Regional Polio Reference Laboratory, National 
Institute for Communicable Diseases, Johannesburg, 
South Africa. Vaccine Preventable Diseases, World 
Health Organization Regional Office for Africa, Braz-
zaville, Congo. Polio Eradication Dept, World Health 
Organization, Geneva, Switzerland. Div of Viral Dis-
TABLE. Number and percentage of nonpolio acute flaccid paralysis (AFP) reported cases among children aged 6–59 months with zero doses,* 










Zero doses 1–3 doses ≥4 doses
Region/State No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
High-incidence northern states† 1,172 206 (17.6) 638 (54.4) 302 (25.8) 1,068 114 (10.7) 542 (50.7) 399 (37.4)
Bauchi 96 13 (13.5) 46 (47.9) 36 (37.5) 78 0 (0.0) 23 (29.5) 55 (70.5)
Jigawa 99 5 (5.1) 69 (69.7) 25 (25.3) 90 4 (4.4) 40 (44.4) 46 (51.1)
Kaduna 140 26 (18.6) 50 (35.7) 64 (45.7) 121 6 (5.0) 45 (37.2) 70 (57.9)
Kano 382 104 (27.2) 184 (48.2) 73 (19.1) 358 61 (17.0) 192 (53.6) 95 (26.5)
Katsina 197 32 (16.2) 111 (56.3) 52 (26.4) 153 14 (9.2) 80 (52.3) 57 (37.3)
Yobe 98 2 (2.0) 67 (68.4) 27 (27.6) 139 10 (7.2) 77 (55.4) 51 (36.7)
Zamfara 160 24 (15.0) 111  (69.4) 25 (15.6) 129 19 (14.7) 85 (65.9) 25 (19.4)
Other northern  states§ 1,233 58 (4.7) 386 (31.3) 778 (63.1) 1,378 30 (2.2) 380 (27.6) 965 (70.3)
Southern states¶ 1,301 26 (2.0) 391 (30.1) 874 (67.2) 1,369 25 (1.8) 375 (27.4) 955 (69.8)
Total 3,706 290 (7.8) 1,415 (38.2) 1,954 (52.7) 3,815 169 (4.4) 1,297 (34.0) 2,319 (60.8)
* Children who have never received an OPV dose, as reported by caregiver. 
† High-incidence states had ≥0.8 confirmed wild poliovirus cases per 100,000 population during 2008.
§ Adamawa, Benue, Borno, Federal Capital Territory, Gombe, Kebbi, Kegi, Kwara, Nasarawa, Niger, Plateau, Sokoto, and Taraba. 
¶ Abia, Akwa Ibom, Anambra, Bayelsa, Cross River, Delta, Ebonyi, Edo, Ekiti, Enugu, Imo, Lagos, Ogun, Ondo, Osun, Oyo, and Rivers.
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FIGURE 2. Local government areas (LGAs) with laboratory-confirmed cases of wild poliovirus type 1 (WPV1) and type 3 (WPV3) — Nigeria, 
January–June 2009 and January–June 2010*
* During 2008, Bauchi, Jigawa, Kaduna, Kano, Katsina, Yobe, and Zamfara had ≥0.8 confirmed WPV cases per 100,000 population and were defined as high-incidence 
northern states. During January–June 2010, confirmed WPV1 in Nigeria occurred only in Sokoto, and WPV3 occurred only in Delta and Zamfara.
January–June 2009
WPV1 (n = 67)
Affected LGAs = 49
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eases and Global Immunization Div, National Center 
for Immunization and Respiratory Diseases, CDC.
Editorial Note
Since 2003, Nigeria has served as the major 
reservoir for WPV1 and WPV3 circulation in West 
Africa and Central Africa (7). Over the past 8 years, 
WPV of Nigerian origin has been imported into 26 
countries in Africa, the Middle East, and Asia, and 
has led to reestablished transmission (>12 months) 
in Chad and Sudan.
Factors related to high WPV incidence in Nigeria 
during the last decade have included loss of public 
confidence in OPV during 2003–2004 (8), long-
standing insufficiencies in health infrastructure result-
ing in low routine vaccination coverage, and poorly 
implemented SIAs that have failed to reach >80% of 
children in high-risk states. With substantial reduc-
tions in WPV1, WPV3, and cVDPV2 cases during 
January–June 2010 compared with the same period 
in 2009, Nigeria has shown substantial progress, sug-
gesting improvements in vaccine coverage with high-
quality SIAs. The increased engagement of traditional, 
religious, and political leadership at the federal, state, 
and local levels has been instrumental in improving 
vaccine acceptance and SIA implementation. If this 
progress can be sustained throughout the upcoming 
season (July–September), during which WPV trans-
mission is traditionally high, WPV transmission in 
Nigeria could be disrupted in the near future. Progress 
elsewhere, including successful implementation of 
synchronized SIAs in West Africa and Central Africa 
to stem regional WPV circulation, would remove a 
potential threat of reimportation into Nigeria and 
ultimately lead to a polio-free Africa. However, 
multiple challenges must be overcome to sustain the 
gains in Nigeria.
Within the seven high-incidence northern states, a 
high proportion of children remain at risk as a result 
of low routine immunization coverage and high birth 
rates. This report indicates that, during 2008–2009, 
a substantial drop occurred in the proportion of chil-
dren with nonpolio AFP who had received no doses of 
vaccine (i.e., from 17.6% in 2008 to 10.7% in 2009) 
in the seven high-incidence states. However, even with 
this decrease, in 2009, a majority of such children 
(50.7%) remained undervaccinated with 1–3 doses 
of OPV. Until the proportion of children vaccinated 
with ≥4 doses is >80% and the proportion of zero-
dose children is <10% in each state, the risk remains 
that WPV transmission will continue (9).
The quality of SIA implementation remains vari-
able and highly dependent on LGA commitment and 
resources, including timely disbursement of funds in 
support of SIAs. Successful implementation of SIAs 
planned for the remainder of 2010 will require ongo-
ing engagement of LGA leadership and supervision, 
with close monitoring of performance indicators at 
the LGA, state, and federal levels. Since emerging in 
2005–2006, cVDPV2 continues to circulate in north-
ern Nigeria. Continued use of high-quality SIAs with 
tOPV will be needed to further control and eliminate 
cVDPV2 transmission, while routine immunization 
services are strengthened. Any new WPV case should 
trigger rapid, type-specific vaccination responses 
(“mop-up” SIAs).
Genomic sequence analysis indicates that some 
chains of WPV transmission during 2009–2010 
have not been detected for more than a year, sug-
gesting limitations in surveillance quality despite 
AFP surveillance performance indicators meeting or 
What is already known on this topic?
In 2008, 798 cases of wild poliovirus (WPV) (48% of 
global cases) were reported in Nigeria, one of four 
remaining countries (including India, Pakistan, and 
Afghanistan) that have never eliminated WPV trans-
mission of both serotypes 1 and 3.
What is added by this report?
From 2008 to 2009, cases of WPV in Nigeria declined 
substantially (from 798 cases to 388), now account-
ing for <1% of reported global WPV cases, and during 
the first 6 months of 2010, only three WPV cases were 
reported. Among children with nonpolio acute flaccid 
paralysis, the decline from 17.6% in 2008 to 10.7% in 
2009 of zero-dose children in high-incidence northern 
states indicates that population immunity might be 
steadily increasing in areas that traditionally have 
been responsible for extensive WPV transmission.
What are the implications for public health practice?
With sustained support of traditional, religious, and 
political leaders to improve implementation of polio 
vaccination activities and to improve surveillance 
for polio cases, Nigeria has the potential to eliminate 
WPV transmission in the near future.
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exceeding targets at national and virtually all state 
levels. Surveillance gaps might be occurring among 
specific subpopulations such as migrants in northern 
Nigeria, including Fulani nomads, who have limited 
access to immunization activities and health-care 
providers. Further efforts to enhance and supplement 
AFP surveillance to detect WPV and cVDPV should 
include seeking reports from nontraditional healers, 
testing waste water for polioviruses, and identifying 
and improving surveillance in LGAs not meeting 
performance criteria.
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Despite recent declines in both incidence and 
mortality, colorectal cancer (CRC) remains the second 
most common cause of cancer deaths after lung can-
cer in the United States (1) and the leading cause of 
cancer deaths among nonsmokers. In 2006 (the most 
recent data available), 139,127 people were diagnosed 
with colorectal cancer, and 53,196 people died (1). 
Screening for colorectal cancer is effective in reducing 
incidence and mortality by removal of premalignant 
polyps and through early detection and treatment of 
CDC Vital Signs is a new series of MMWR 
reports that will announce the latest 
results for key public health indicators. 
Vital Signs: Colorectal Cancer Screening Among Adults 
Aged 50–75 Years — United States, 2008
On July 6, this report was posted as an MMWR Early Release on the MMWR website (http://www.cdc.gov/mmwr).
ABSTRACT
Background: Colorectal cancer (CRC) remains the second leading cause of cancer deaths in 
the United States and the leading cause of cancer deaths among nonsmokers. Statistical mod-
eling indicates that, if current trends in health behaviors, screening, and treatment continue, 
U.S. residents can expect to see a 36% decrease in the CRC mortality rate by 2020, compared 
with 2000.
Methods: Every 2 years, CDC uses Behavioral Risk Factor Surveillance System data to estimate 
up-to-date CRC screening prevalence in the United States. Adults aged ≥50 years were con-
sidered to be up-to-date with CRC screening if they reported having a fecal occult blood test 
(FOBT) within the past year or lower endoscopy (i.e., sigmoidoscopy or colonoscopy) within 
the preceding 10 years. Prevalence was calculated for adults aged 50–75 years based on current 
U.S. Preventive Services Task Force recommendations.
Results: For 2008, the overall age-adjusted CRC screening prevalence for the United States was 
62.9% among adult respondents aged 50–75 years, increased from 51.9% in 2002. Among 
the lowest screening prevalences were those reported by persons aged 50–59 years (53.9%), 
Hispanics (49.8%), persons with lower income (47.6%), those with less than a high school 
education (46.1%), and those without health insurance (35.6%). 
Conclusions: CRC screening rates continue to increase in the United States. Underscreening 
persists for certain racial/ethnic groups, lower socioeconomic groups, and the uninsured.
Implications for Public Health Practice: Health reform is anticipated to reduce financial 
barriers to CRC screening, but many factors influence CRC screening. The public health and 
medical communities should use methods, including client and provider reminders, to ensure 
test completion and receipt of follow-up care. Public health surveillance should be expanded and 
communication efforts enhanced to help the public understand the benefits of CRC screening.
cancer (2). CRC screening prevalence has improved 
over the past decade (3); however, in 2006, approxi-
mately 30% of eligible U.S. residents had never been 
screened for CRC (3). This Vital Signs report updates 
screening prevalence in the United States using data 
from the 2008 Behavioral Risk Factor Surveillance 
System (BRFSS) survey for persons aged 50–75 years, 
based on recommendations for up-to-date CRC 
screening from the U.S. Preventive Services Task Force 
(USPSTF) (4). 
Methods
BRFSS is a state-based, random-digit dialed 
telephone survey of the civilian, noninstitutional-
ized adult population that collects information on 
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use declined from 20.9% of CRC screening in 2002 
to 14.1% in 2008.
Conclusions and Comment
The results in this Vital Signs report indicate that 
the prevalence of up-to-date CRC screening in the 
United States is continuing to increase. An increase 
(from 38% in 2000 to 53% in 2008) also has been 
reported using National Health Interview Survey 
data (6). However, in 2008, certain populations in 
the United States remained underscreened, including 
those with lower socioeconomic status, Hispanics, 
and those without health insurance. Multiple factors 
might explain these differences, including patient 
education and income, as well as provider and clinical 
systems factors. As in previous surveys, the 2008 sur-
vey indicated notable geographic differences in CRC 
screening prevalence. The reasons for these geographic 
differences remain unknown, but screening capac-
ity, lack of physician availability, and patient factors 
including income, education, and lack of awareness 
have been proposed as reasons (6). 
CRC screening rates continue to increase in the 
United States. Additional improvements in screen-
ing prevalence might have substantive impact on 
CRC mortality. Statistical modeling indicates that, 
if current trends in health behaviors, screening, and 
treatment continue, U.S. residents can expect to see 
a 36% decrease in the CRC mortality rate by 2020, 
compared with 2000 (7).
Insufficient evidence exists to recommend “one 
best” test for CRC screening. Several proven, effec-
tive tests exist and are recommended by USPSTF, 
including annual FOBT, sigmoidoscopy every 5 years, 




for every 10% increase in colonoscopy 
screening.
•	 Only	36%	of	men	and	women	without	




health risk behaviors, preventive health practices, and 
health-care access in the United States (5). Every 2 
years (in even numbered years), respondents aged ≥50 
years are asked whether they have ever used a “special 
kit at home to determine whether the stool contains 
blood (fecal occult blood test [FOBT]),” whether 
they have ever had a “tube inserted into the rectum 
to view the colon for signs of cancer or other health 
problems (sigmoidoscopy or colonoscopy),” and when 
these tests were last performed. CDC calculated the 
prevalence of adults who reported having had an 
FOBT within the past year or lower endoscopy (i.e., 
sigmoidoscopy or colonoscopy) within the preceding 
10 years, as was done in previous reports (3). Based on 
the U.S. Preventive Services Task Force recommended 
screening age, this analysis was restricted to persons 
aged 50–75 years (4). Data were aggregated across all 
50 states and the District of Columbia. Respondents 
who refused to answer, had a missing answer, or who 
answered “don’t know/not sure” were excluded from 
analysis of the question. 
The median Council of American Survey and 
Research Organizations (CASRO) response rate was 
53.3%, and the median CASRO cooperation rate 
was 75.0% (5). Data were weighted to the age, sex, 
and racial/ethnic distribution of each state’s adult 
population using intercensal estimates and were age-
standardized to the 2008 BRFSS population. 
Results
The 2008 BRFSS survey was administered to 
414,509 respondents, of whom 201,157 were aged 
50–75 years. The overall, age-adjusted combined up-
to-date CRC screening (FOBT and lower endoscopy) 
prevalence for the United States was 62.9% among 
adult respondents aged 50–75 years (Table). Among 
the lowest screening prevalences were those reported 
by persons aged 50–59 years (53.9%), Hispanics 
(49.8%), persons with lower income (47.6%), those 
with less than a high school education (46.1%), and 
those without health insurance (35.6%). Similar pat-
terns were noted for FOBT in the preceding year and 
for lower endoscopy in the preceding 10 years. The 
percentage of persons up-to-date with CRC screen-
ing ranged from 53.2% in Oklahoma to 74.1% in 
Massachusetts (Figure 1). States with the highest 
screening prevalence were concentrated in the north-
eastern United States. CRC screening increased from 
51.9% in 2002 to 62.9% in 2008 (Figure 2). During 
that period, use of endoscopy increased, while FOBT 
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and colonoscopy every 10 years (4). In addition to 
maximizing prevalence of CRC screening to reduce 
morbidity and mortality, ensuring proper follow-up 
of abnormal results is important to maximize the 
benefits of screening (4). 
The findings in this report are subject to at least 
three limitations. First, because BRFSS is a telephone 
survey of residential households, only adults in house-
holds with landline telephones are represented; there-
fore, the results might not be representative of the U.S. 
population. Evidence suggests that adults living in 
wireless-only households tend to be younger and have 
lower incomes, and are more likely to be members of 
minority populations, which might result in either 
underestimates or overestimates. Second, responses 
are self-reported and not confirmed by review of 
medical records. Finally, the survey response rate was 
low, which increases the risk for response bias.
Policy changes in the Patient Protection and 
Affordable Care Act are expected to remove financial 
barriers to CRC screening by expanding insurance 
coverage and eliminating cost sharing in Medicare 
and private plans, but additional barriers remain 
(8). Evidence-based, systems-change interventions, 
including client and provider reminders to ensure 
test completion and receipt of follow-up care, have 
been shown by the Guide to Community Preventive 
Services* to increase CRC screening; however, these 
approaches have not been widely adopted in clinical 
TABLE. Percentage of respondents aged 50–75 years who reported receiving a fecal occult blood test (FOBT) within 1 
year, or a lower endoscopy* within 10 years, by selected characteristices — Behavioral Risk Factor Surveillance System 
(BRFSS), United States, 2008†
Characteristic
FOBT within 1 yr
Lower endoscopy 
within 10 yrs
FOBT within 1 yr or lower 
endoscopy within 10 yrs
% (95% CI§) % (95% CI) % (95% CI)
Overall 14.1 (13.8–14.4) 58.5 (58.1–59.0) 62.9 (62.5–63.3)
Age group (yrs)
50–59 11.0 (10.6–11.4) 49.7 (49.0–50.3) 53.9 (53.3–54.5)
60–69 17.0 (16.5–17.6) 66.7 (66.0–67.3) 71.1 (70.5–71.7)
70–75 18.2 (17.4–19.1) 71.4 (70.4–72.3) 75.8 (74.8–76.7)
Sex
Men 14.6 (14.2–15.1) 59.0 (58.4–59.7) 63.2 (62.6–63.9)
Women 13.6 (13.2–13.9) 58.1 (57.6–58.6) 62.6 (62.0–63.1)
Race
White 13.8 (13.5–14.1) 59.8 (59.4–60.2) 63.9 (63.5–64.4)
Black 17.2 (16.0–18.6) 56.6 (55.0–58.2) 62.0 (60.5–63.6)
Asian/Pacific Islander 13.5 (11.0–16.6) 51.1 (47.2–55.0) 55.5 (51.6–59.4)
American Indian/Alaska Native 15.1 (12.3–18.3) 50.7 (46.7–54.6) 54.4 (50.4–58.4)
Other 11.8 (9.7–14.1) 43.7 (40.6–46.9) 49.3 (46.1–52.6)
Ethnicity
Hispanic 12.0 (10.5–13.7) 45.8 (43.6–48.0) 49.8 (47.6–52.0)
Non-Hispanic 14.3 (14.0–14.6) 59.8 (59.4–60.2) 64.2 (63.8–64.6)
Education level
< High school 11.3 (10.4–12.3) 41.8 (40.1–43.5) 46.1 (44.4–47.8)
High school graduate/GED¶ 13.3 (12.8–13.8) 53.3 (52.5–54.0) 58.1 (57.3–58.8)
Some college/tech school 15.0 (14.4–15.6) 59.2 (58.4–60.0) 63.7 (63.0–64.5)
College graduate 14.9 (14.3–15.4) 66.9 (66.3–67.6) 70.6 (70.0–71.3)
Annual household income ($)
 <15,000 11.8 (10.8–12.8) 42.3 (40.7–43.9) 47.6 (46.0–49.3)
 15,000–34,999 13.9 (13.2–14.6) 48.9 (48.0–49.8) 54.0 (53.0–54.9)
 35,000–49,999 13.7 (13.0–14.4) 57.1 (56.0–58.1) 61.3 (60.2–62.3)
 50,000–74,999 14.1 (13.4–14.9) 62.7 (61.7–63.7) 66.5 (65.5–67.4)
 ≥75,000 15.0 (14.4–15.6) 69.4 (68.6–70.1) 72.9 (72.2–73.6)
Health insurance
Yes 14.6 (14.3–14.9) 61.3 (60.9–61.8) 65.7 (65.3–66.1)
No 8.9 (7.9–10.1) 31.3 (29.2–33.5) 35.6 (33.4–37.9)
* Sigmoidoscopy or colonoscopy.
† Percentages standardized to the age distribution in the 2008 BRFSS survey.
§ Confidence interval.
¶ General Educational Development certificate.
* Additional information available at http://www.thecommunityguide.
org/index.html.
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practice. Physician recommendation remains an 
important but underutilized facilitator of CRC 
screening. Improving cancer screening benchmarks 
in clinical practice should be a high priority for 
new patient-care improvement models such as the 
patient-centered medical home (9). Case manage-
ment approaches such as patient navigation models to 
maximize patient participation and ensure adequate 
follow-up also appear promising (10). Utah has used 
multiple approaches to improve its CRC screening 
prevalence. Reported use of CRC endoscopy increased 
from 32.1% in 1999 to 51.9% in 2005 through the 
use of small media (e.g., videos, letters, brochures, and 
flyers) and large media campaigns and by providing 
CRC screening tests (mainly FOBT) for those who 
could not afford it.†
CDC’s CRC screening program, funded in 2009, 
places emphasis on population-based approaches to 
increase CRC screening.§ The program is based on 
the recommendations of the Guide to Community 
Preventive Services, which has identified evidence-
based interventions to increase cancer screening in 
communities by targeting providers and the general 
population. Full implementation of these recommen-
dations, including a focus on reaching disadvantaged 
populations, can achieve the goal of more complete 
population coverage.
Surveillance of cancer screening and diagnostic 
activities currently is limited to population surveys 
and is only collected every other year by BRFSS. 
Additional surveillance efforts might guide popula-
tion-based outreach, identify and target unscreened 
populations, and ensure adequate follow-up (10). 
CDC and state and local health departments should 
develop and monitor centralized population-based 
registries of persons eligible for screening, provide 
appropriate outreach, and ensure adequate follow-
up. These registries could be developed to track and 
promote screening awareness and subsequent utiliza-
tion through communication media (e.g., telephone, 
mail, or electronic reminders) or use of peer outreach. 
Registries of underserved populations, including 
Medicaid enrollees and those without a regular pro-
vider, could be used to promote screening among 
persons in vulnerable populations at greater risk. 
FIGURE 2. Percentage of respondents aged 50–75 years 
who reported receiving a fecal occult blood test (FOBT) 
within 1 year or a lower endoscopy* within 10 years — 
Behavioral Risk Factor Surveillance System (BRFSS), United 



















* Sigmoidoscopy or colonoscopy.
† Percentages standardized to the age distribution in the 2008 BRFSS 
survey.
FIGURE 1. Percentage of respondents aged 50–75 years who reported receiving 
a fecal occult blood test (FOBT) within 1 year or a lower endoscopy* within 10 







* Sigmoidoscopy or colonoscopy.
† Percentages standardized to the age distribution in the 2008 BRFSS survey.
† Additional information available at http://health.utah.gov/ucan/
partners/pub/pdfs/utahcancerplan080206.pdf.
§ Available at http://www.cdc.gov/cancer/crccp.
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Breast cancer remains the most commonly diag-
nosed cancer and the second leading cause of cancer 
deaths among women in the United States. In 2006 
(the most recent data available), approximately 
191,410 women were diagnosed with invasive breast 
cancer, and 40,820 women died (1). The incidence 
and mortality have been declining since 1996 at a 
rate of approximately 2% per year (2), possibly as a 
result of widespread screening with mammography 
and the development of more effective therapies (3). 
Mammography use declined slightly in 2004, but rose 
again in 2006 (4,5). This Vital Signs report updates 
mammography screening prevalence in the United 
States, using data from the 2008 Behavioral Risk 
Factor Surveillance System (BRFSS).
Vital Signs: Breast Cancer Screening Among Women 
Aged 50–74 Years — United States, 2008
On July 6, this report was posted as an MMWR Early Release on the MMWR website (http://www.cdc.gov/mmwr).
ABSTRACT
Background: Breast cancer remains the second leading cause of cancer deaths for women in the 
United States. Screening with treatment has lowered breast cancer mortality.
Methods: Every 2 years, CDC uses Behavioral Risk Factor Surveillance System data to estimate 
mammography prevalence in the United States. Up-to-date mammography prevalence is calcu-
lated for women aged 50–74 years who report they had the test in the preceding 2 years.
Results: For 2008, overall, age-adjusted, up-to-date mammography prevalence for U.S. women 
aged 50–74 years was 81.1%, compared with 81.5% in 2006. Among the lowest prevalences 
reported were those by women aged 50–59 years (79.9%), persons who did not finish high 
school (72.6%), American Indian/Alaska Natives (70.4%), those with annual household income 
<$15,000 (69.4%), and those without health insurance (56.3%). Highest mammography 
prevalence was among residents of the northeastern United States.
Conclusions: In recent years, mammography rates have plateaued. Critical gaps in screen-
ing remain for certain racial/ethnic groups and lower socioeconomic groups, and for the 
uninsured.
Implications for Public Health Practice: Health-care reform is likely to increase access by 
increasing insurance coverage and by reducing out-of-pocket costs for mammography screening. 
Widespread implementation of evidence-based interventions also will be needed to increase 
screening rates. These include patient and provider reminders to schedule a mammogram, use 
of small media (e.g., videos, letters, brochures, and flyers), one-on-one education of women, 
and reduction of structural barriers (e.g., more convenient hours and attention to language, 
health literacy, and cultural factors).
Methods
BRFSS is a state-based, random-digit-dialed 
telephone survey of the civilian, noninstitutional-
ized adult population that collects information on 
health risk behaviors, preventive health practices, and 
health-care access in the United States (6). Every 2 
years (even numbered years), adult female respondents 
are asked whether they have ever had a mammogram. 
Respondents who answer “yes” are then asked how 
long it has been since their last mammogram. For this 
report, breast cancer screening prevalence was calcu-
lated for women aged 50–74 years based on United 
States Preventive Services Task Force (USPSTF) rec-
ommendations, which considers women to be up-to-
date if they received a mammogram in the preceding 
2 years (7). Respondents who refused to answer, had 
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prevalences reported were those by women aged 
50–59 years (79.9%), persons who did not finish 
high school (72.6%), American Indian/Alaska Natives 
(70.4%), those with annual household income 
<$15,000 (69.4%), and those without health insur-
ance (56.3%). Mammography screening prevalence 
varied by state, with the highest mammography use 
in the northeastern United States. Among states, 
screening prevalence ranged from 72.1% in Nevada 
to 89.8% in Massachusetts (Figure 1). Nationally, 
up-to-date mammography screening increased from 
77.5% in 1997 to 81.1% in 2008 (Figure 2).
Conclusions and Comment
After mammography was shown to be effective in 
lowering morbidity and mortality from breast cancer 
in the early 1990s, it was adopted rapidly for the early 
detection of breast cancer (3). However, as this Vital 
Signs report confirms, mammography utilization has 
leveled off in the last decade (4,5). Other population-
based surveys have shown a similar plateau in rates. 
Results from the 2008 National Health Interview 
Survey indicate comparable mammography screening 
for women aged 50–64 and 65–74 years (74.2% and 
72.6%, respectively)(4).
In 2000, the U.S. Department of Health and 
Human Services set a Healthy People 2010 target to 
increase to 70% the proportion of women aged >40 
years who had a mammogram within the past 2 years.* 
The target was met in 2003 and exceeded by 11 per-
centage points in 2008. Nonetheless, approximately 
7 million eligible women in the United States are not 
being screened regularly, and they remain at greater 
risk of death from breast cancer. One recent report 
estimated that as many as 560 breast cancer deaths 
could be prevented each year with each 5% increase 
in mammography (8). One successful program that 
reaches out to minority, low income, uninsured 
women is the National Breast and Cervical Cancer 
Early Detection Program.† The program has provided 
high quality screening, diagnostic and treatment ser-
vices for the past 20 years. 
Mammography utilization is influenced by 
multiple factors, including patient and provider 
characteristics, health-care norms, and access to and 
availability of health-care services. Similar to previous 
a missing answer, or answered “don’t know/not sure” 
were excluded.
The median Council of American Survey and 
Research Organizations (CASRO) response rate 
was 53.3%, and the median CASRO cooperation 
rate was 75.0% (6). Data were weighted to the age, 
sex, and racial and ethnic distribution of each state’s 
adult population using intercensal estimates and 
were age-standardized to the 2008 BRFSS female 
population. 
Results
In 2008, the BRFSS survey was administered to 
414,509 respondents, of whom 120,095 were women 
aged 50–74 years. The age-adjusted prevalence of 
up-to-date mammography for women overall in the 
United States was 81.1% (Table). Among the lowest 
TABLE. Percentage of women aged 50–74 years who 
reported receiving up-to-date* mammography, by selected 
characteristics — Behavioral Risk Factor Surveillance 
System (BRFSS), United States, 2008†
Characteristic No. % (95% CI§)
Total 117,450 81.1 (80.7–81.6)
Age group (yrs)
50–59 52,421 79.9 (79.2–80.5)
60–69 46,711 82.4 (81.8–83.0)
70–74 18,318 82.7 (81.7–83.7)
Race 
White 101,245 81.4 (81.0–81.8)
Black 9,805 82.1 (80.5–83.7)




Other 2,257 77.0 (73.4–80.3)
Ethnicity
Hispanic 4,886 81.4 (79.1–83.4)
Non-Hispanic 112,115 81.1 (80.7–81.5)
Education level
<High school 10,323 72.6 (70.6–74.5)
High school graduate/GED¶ 37,975 78.6 (77.8–79.3)
Some college/tech school 32,819 81.1 (80.3–81.8)
College graduate 36,177 86.2 (85.5–86.8)
Annual household income ($)
  <15,000 12,744 69.4 (67.6–71.1)
 15,000–34,999 31,678 74.2 (73.2–75.3)
 35,000–49,999 16,382 82.0 (80.8–83.0)
 50,000–74,999 17,098 84.8 (83.9–85.8)
 ≥75,000 23,059 87.9 (87.1–88.7)
Health insurance
Yes 107,780 83.8 (83.4–84.2)
No 9,536 56.3 (53.2–59.5)
* Within the preceding 2 years. 
† Percentages standardized to the age distribution in the 2008 BRFSS 
survey.
§ Confidence interval.
¶ General Eduction Development certificate.
* Additional information available at http://www.healthypeople.gov.
† Additional information available at http://www.cdc.gov/cancer/
nbccedp.
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analyses, the analysis in this report found pockets 
of mammography underscreening among several 
large U.S. populations. For example, the screening 
rate varied considerably by geography and was low-
est in west-central states, the states with the lowest 
population densities§ as well as the states with the 
fewest mammography facilities.¶ A study from Texas 
highlighted the association between mammography 
supply and mammography use at the county level. 
Counties with no mammography units had the lowest 
mammography utilization (9).
The passage of the Patient Protection and 
Affordability Act should remove the financial barrier 
to mammography screening by expanding coverage 
and eliminating cost sharing in Medicare and pri-
vate plans; however, barriers remain. For example, 
in 2008 the difference in mammography prevalence 
between women with and without health insurance 
was 27.5%. Even among women with health insur-
ance, 16.2% had not received mammography in the 
preceding 2 years. Similar differences in receipt of 
mammography by insurance status were noted in a 
2009 study (9). These findings suggest new roles for 
public health to improve screening through increased 
education of women and providers, and through 
additional targeted outreach to underscreened groups 
including lower SES, uninsured and select minority 
groups. Several evidence-based interventions are 
recommended by the Guide to Community Preventive 
Services to increase mammography screening in 
communities.** These include sending client remind-
ers to women, using small media (e.g., videos, letters, 
flyers, and brochures), and reducing structural barriers 
(e.g., providing more convenient hours and increasing 






for each 5% increase in mammography. 
•	 Additional	information	is	available	at	
http://www. cdc.gov/vitalsigns.
§ Additional information available at http://www.frontierus.org/ 
2000update.htm and http://www.shepscenter.unc.edu/rural/maps/
Frontier_counties07.pdf.
¶ Additional information available at http://www.gao.gov/new.items/
d06724.pdf.
FIGURE 2. Percentage of women aged 50–74 years who 
reported receiving up-to-date* mammography — 
Behavioral Risk Factor Surveillance System (BRFSS), 
















* Within the preceding 2 years.
† Percentages standardized to the age distribution in the 2008 BRFSS 
survey.
FIGURE 1. Percentage of women aged 50–74 years who reported receiving 
up-to-date* mammography, by state — Behavioral Risk Factor Surveillance 






* Within the preceding 2 years.
† Percentages standardized to the age distribution in the 2008 BRFSS survey.
 ** Additional information available at http://www.thecommunity 
guide.org/index.htm.
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attention to language, health literacy, and cultural 
factors). Surveillance with targeted outreach, case 
management, and quality assurance through systems 
change are productive future roles for public health 
agencies to improve the delivery of clinical preventive 
services in the era of health reform.
The findings in this report are subject to at least 
three limitations. First, because BRFSS is a telephone 
survey of residential households, only women in 
households with landline telephones participated; 
therefore, the results might not be representative of 
all women. Second, responses are self-reported and 
not confirmed by review of medical records. Finally, 
the survey response rate was low, which increases the 
risk for response bias.
Many factors influence a woman’s intent and 
ability to access screening services, including socio-
economic status, awareness of the benefits of screen-
ing, and mammography acceptability and availability 
(10). However, the most common reason women give 
for not having a mammogram is that no one recom-
mended the test; therefore, health-care providers have 
the most important role in increasing the prevalence 
of up-to-date mammography among women in the 
United States (10).
Reported by
LC Richardson, MD, SH Rim, MPH, M Plescia, MD, 
Div of Cancer Prevention and Control, National Center 
for Chronic Disease Prevention and Health Promotion, 
CDC.
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birthing hospitals and local health departments to 
support postpartum vaccination of mothers and close 
contacts of newborns.
Reported by
K Winter, MPH, K Harriman, PhD, R Schechter, MD, 
E Yamada, MD, J Talarico, DO, G Chavez, MD, Cali-
fornia Dept of Public Health.
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Salmonella Newport Infections Associated 
with Consumption of Unpasteurized 
Milk — Utah, April–June 2010
On April 29, 2010, the Utah Department of 
Health (UDOH) was notified of three cases of 
Salmonella enterica serotype Newport infection. The 
three patients recently had consumed unpasteurized 
milk purchased from a store in northern Utah (store 
A). In Utah, unpasteurized milk can be sold legally at 
licensed dairies or by licensed dairies at dairy-owned 
retail stores meeting specific requirements (1). A 
central Utah dairy licensed to sell unpasteurized milk 
(dairy A) owns and sells unpasteurized milk at store A 
and a second northern Utah store (store B). By May 3, 
2010, three additional patients with S. Newport infec-
tions had been reported; all recently had consumed 
unpasteurized milk purchased from store A. UDOH 
notified the Utah Department of Agriculture and 
Food (UDAF) of the suspected association between 
illness and unpasteurized milk consumption, and 
UDAF suspended sales of unpasteurized milk at the 
two stores on May 3, 2010.
During April 29–June 3, 2010, a total of 10 
S. Newport cases were reported to UDOH; all 10 
patients had consumed unpasteurized milk from 
store A (seven patients) or store B (three patients). 
The patients ranged in age from 2 to 56 years 
(median: 21 years); six were female. One patient was 
Pertussis — California, January–June 2010
The number of pertussis cases reported to the 
California Department of Public Health (CDPH) 
has increased substantially during 2010. The increase 
in cases was first noted in late March among patients 
admitted to a children’s hospital. During January 1– 
June 30, 2010, a total of 1,337 cases were reported, a 
418% increase from the 258 cases reported during the 
same period in 2009. All cases either met the Council 
of State and Territorial Epidemiologists definitions 
for confirmed or probable pertussis or had an acute 
cough illness and Bordetella pertussis–specific nucleic 
acid detected by polymerase chain reaction from 
nasopharyngeal specimens (1).
During January–June in California, the incidence 
of pertussis was 3.4 cases per 100,000 population. 
County rates ranged from zero to 76.9 cases per 
100,000 (median: 2.0 cases). By age group, incidence 
was highest (38.5 cases per 100,000) among infants 
aged <1 year; 89% of cases were among infants aged 
<6 months, who are too young to be fully immu-
nized. Incidence among children aged 7–9 years and 
10–18 years was 10.1 cases and 9.3 cases per 100,000, 
respectively.
Of 634 case reports with available data, 105 
(16.6%) patients were hospitalized, of whom 66 
(62.9%) were aged <3 months. Incidence among 
Hispanic infants (49.8 cases per 100,000) was higher 
than among other racial/ethnic populations. Five 
deaths were reported, all in previously healthy Hispanic 
infants aged <2 months at disease onset; none had 
received any pertussis-containing vaccines.
The incidence of pertussis is cyclical, with peaks 
occurring every 3–5 years in the United States (2). The 
last peak was in 2005, when approximately 25,000 
cases were reported nationally and approximately 
3,000 cases in California, including eight deaths in 
infants aged <3 months. If the rates from the first half 
of the year persist throughout 2010, California would 
have its highest annual rate of pertussis reported since 
1963 and the most cases reported since 1958.
CDPH is attempting to prevent transmission of 
pertussis to vulnerable infants (3) by disseminating 
educational materials and clinical guidance, raising 
community awareness, and offering free tetanus, 
diphtheria, and acellular pertussis (Tdap) vaccine to 
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MMWR on Facebook and Twitter
MMWR reports now can be accessed on social 
networking websites Facebook and Twitter. Readers 
can download and comment on MMWR weekly 
reports, recommendations and reports, surveillance 
summaries, and podcasts from the MMWR website. 
Readers can follow MMWR on Facebook by visiting 
http://www.facebook.com/cdcmmwr, and on Twitter 
by visiting http://www.twitter.com/cdcmmwr.
hospitalized. Isolates from all 10 patients were identi-
fied as indistinguishable by two-enzyme pulsed-field 
gel electrophoresis (PFGE), with pattern combination 
UTJJPX01.098/UTJJPA26.009, and were sensitive to 
routinely used antibiotics. Cultures of frozen, unpas-
teurized milk samples stored at dairy A from batches 
of milk sold during the outbreak period yielded S. 
Newport isolates indistinguishable by PFGE from 
the outbreak strain. An inspection of dairy A on 
May 7, 2010, did not reveal any obvious sources of 
contamination.
On May 12, 2010, on the basis of coliform test 
results within legal limits, the dairy was permitted to 
resume sales of unpasteurized milk. Ongoing test-
ing includes monthly screening for Salmonella spp. 
in retail samples of unpasteurized milk. As of June 
21, 2010, no additional cases had been reported 
to UDOH. Consumption of unpasteurized dairy 
Announcement
products poses a risk for foodborne illness (2), and 
consumers of unpasteurized milk should be aware 
of this risk.
Reported by
JM Hall, MPH, RT Rolfs, MD, RK Herlihy, MD, MPS 
Dimond, MPH, Bur of Epidemiology, Utah Dept of 
Health; J Holbrook, MPH, Utah County Health Dept; 
LH Smith, JM Wagner, Unified State Laboratories: 
Public Health, Utah Dept of Health; RW Clark, MPH, 
Utah Dept of Agriculture and Food. WA Lanier, DVM, 
EIS Officer, CDC.
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QuickStats 
FROM THE NATIONAL CENTER FOR HEALTH STATISTICS
Never-Married Females and Males Aged 15–19 Years Who Have 
Ever Had Sexual Intercourse* — National Survey of Family Growth, 
United States, 1988–2008
* Based on responses by females to the question, “At any time in your life have you ever had sexual intercourse 
with a man, that is, made love, had sex, or gone all the way?” and by males to the question, “Have you ever had 
sexual intercourse with a female (sometimes this is called making love, having sex, or going all the way)?”
† 95% confidence interval.
From 1988 to 2006–2008, the percentage of never-married teenage females (ages 15–19 years) who ever had sexual intercourse 
declined from 51% to 42%, and the percentage for never-married teenage males declined from 60% to 43%. In 1988, teenage 
males were more likely than teenage females to have ever have had sexual intercourse, but by 2006–2008, the percentages 
were equivalent.
Source: Abma JC, Martinez GM, Copen CE. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, National Survey 
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TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending 









Total cases reported 
for previous years States reporting cases 
during current week (No.)2009 2008 2007 2006 2005
Anthrax — — — 1 — 1 1 —
Botulism, total — 35 3 118 145 144 165 135
 foodborne — 4 0 10 17 32 20 19
 infant — 23 2 83 109 85 97 85
 other (wound and unspecified) — 8 1 25 19 27 48 31
Brucellosis — 53 2 115 80 131 121 120
Chancroid 1 27 0 28 25 23 33 17 NY (1)
Cholera — 2 0 10 5 7 9 8
Cyclosporiasis§ 8 54 10 141 139 93 137 543 NY (1), FL (7)
Diphtheria — — — — — — — —
Domestic arboviral diseases § ,¶:
 California serogroup virus disease — — 2 55 62 55 67 80
 Eastern equine encephalitis virus disease — 1 0 4 4 4 8 21
 Powassan virus disease — 1 0 6 2 7 1 1
 St. Louis encephalitis virus disease — — 1 12 13 9 10 13
 Western equine encephalitis virus disease — — — — — — — —
Haemophilus influenzae,** invasive disease (age <5 yrs):
 serotype b — 7 0 35 30 22 29 9
 nonserotype b — 94 4 236 244 199 175 135
 unknown serotype 3 113 3 178 163 180 179 217 PA (1), OH (2)
Hansen disease§ 1 18 2 103 80 101 66 87 MD (1)
Hantavirus pulmonary syndrome§ — 4 1 20 18 32 40 26
Hemolytic uremic syndrome, postdiarrheal§ 3 70 7 242 330 292 288 221 NY (2), FL (1)
HIV infection, pediatric (age <13 yrs)†† — — 1 — — — — 380
Influenza-associated pediatric mortality§,§§ — 54 2 359 90 77 43 45
Listeriosis 6 283 17 852 759 808 884 896 PA (1), OH (1), OK (1), CO (1), WA (1), OR (1)
Measles¶¶ — 28 4 71 140 43 55 66
Meningococcal disease, invasive***:
 A, C, Y, and W-135 1 132 5 301 330 325 318 297 CT (1)
 serogroup B 2 62 4 174 188 167 193 156 NY (1), TX (1)
 other serogroup 1 6 0 23 38 35 32 27 OK (1)
 unknown serogroup 5 206 11 482 616 550 651 765 NE (1), FL (1), OR (1), CA (2)
Mumps 5 2,064 21 1,991 454 800 6,584 314 NY (5)
Novel influenza A virus infections††† — 1 0 43,771 2 4 NN NN
Plague — — 0 8 3 7 17 8
Poliomyelitis, paralytic — — — 1 — — — 1
Polio virus Infection, nonparalytic§ — — — — — — NN NN
Psittacosis§ — 4 0 9 8 12 21 16
Q fever, total§,§§§ 1 47 4 113 120 171 169 136
 acute 1 36 2 93 106 — — — FL (1)
 chronic — 11 0 20 14 — — —
Rabies, human — 1 0 4 2 1 3 2
Rubella¶¶¶ 1 4 0 3 16 12 11 11 CA (1)
Rubella, congenital syndrome — — — 2 — — 1 1
SARS-CoV§,**** — — — — — — — —
Smallpox§ — — — — — — — —
Streptococcal toxic-shock syndrome§ — 91 2 162 157 132 125 129
Syphilis, congenital (age <1 yr)†††† — 80 8 423 431 430 349 329
Tetanus — 1 1 18 19 28 41 27
Toxic-shock syndrome (staphylococcal)§ 1 45 2 74 71 92 101 90 MI (1)
Trichinellosis — 1 1 13 39 5 15 16
Tularemia 6 22 5 93 123 137 95 154 IN (2), MO (2), NE (2)
Typhoid fever 6 164 6 399 449 434 353 324 MD (1), NV (1), WA (1), CA (3)
Vancomycin-intermediate Staphylococcus aureus§ 8 50 1 78 63 37 6 2 NY (2), OH (1), MO (4), FL (1)
Vancomycin-resistant Staphylococcus aureus§ — 1 — 1 — 2 1 3
Vibriosis (noncholera Vibrio species infections)§ 16 162 8 790 588 549 NN NN MD (4), SC (1), GA (1), FL (5), WA (4), CA (1)
Viral hemorrhagic fever§§§§ — 1 — NN NN NN NN NN
Yellow fever — — — — — — — —
See Table I footnotes on next page.
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Notifiable Disease Data Team and 122 Cities Mortality Data Team
 Patsy A. Hall-Baker
Deborah A. Adams  Rosaline Dhara
Willie J. Anderson  Pearl C. Sharp
Jose Aponte  Michael S. Wodajo
Lenee Blanton
* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the 
past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week 
totals.
FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week 



























TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week 
ending July 3, 2010 (26th week)*
—: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts.
 * Incidence data for reporting years 2009 and 2010 are provisional, whereas data for 2005 through 2008 are finalized.
 † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. 
Additional information is available at http://www.cdc.gov/ncphi/disss/nndss/phs/files/5yearweeklyaverage.pdf.
 § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table except starting in 2007 for the domestic arboviral diseases, STD data, TB 
data, and influenza-associated pediatric mortality, and in 2003 for SARS-CoV.  Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
 ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and 
Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
 ** Data for H. influenzae (all ages, all serotypes) are available in Table II.
 †† Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences 
the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is 
completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
 §§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Since April 26, 2009, a total of 286 influenza-associated pediatric 
deaths associated with 2009 influenza A (H1N1) virus infection have been reported. Since August 30, 2009, a total of 279 influenza-associated pediatric deaths occurring during the 
2009–10 influenza season have been reported. A total of 133 influenza-associated pediatric deaths occurring during the 2008-09 influenza season have been reported.
 ¶¶ No measles cases were reported for the current week.
 *** Data for meningococcal disease (all serogroups) are available in Table II.
 ††† CDC discontinued reporting of individual confirmed and probable cases of 2009 pandemic influenza A (H1N1) virus infections on July 24, 2009.   During 2009, three cases of novel 
influenza A virus infections, unrelated to the 2009 pandemic influenza A (H1N1) virus, were reported to CDC.  The one case of novel influenza A virus infection reported to CDC during 
2010 was identified as swine influenza A (H3N2) virus and is unrelated to pandemic influenza A (H1N1) virus.
 §§§ In 2009, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with 
respect to acute and chronic Q fever cases.
 ¶¶¶ The one rubella case reported for the current week was unknown.
 **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.
 †††† Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
 §§§§ There was one case of viral hemorrhagic fever reported during week 12. The one case report was confirmed as lassa fever. See Table II for dengue hemorrhagic fever.
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TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending July 3, 2010, and July 4, 2009 (26th week)*
Reporting area
Chlamydia trachomatis infection Cryptosporidiosis
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 10,018 22,061 26,080 523,942 625,532 84 116 284 2,558 2,678
New England 640 743 1,396 18,838 19,888 2 6 40 130 173
Connecticut — 210 736 4,023 5,874 — 0 36 36 38
Maine† 39 49 75 1,229 1,257 1 1 4 28 18
Massachusetts 445 395 638 10,087 9,413 — 1 15 — 51
New Hampshire 57 38 122 1,121 1,051 — 1 6 28 27
Rhode Island† 81 70 130 1,773 1,694 — 0 8 7 4
Vermont† 18 23 63 605 599 1 1 9 31 35
Mid. Atlantic 2,438 3,182 4,619 82,008 77,902 16 15 38 291 302
New Jersey 380 440 624 10,831 12,395 — 0 5 — 21
New York (Upstate) 505 657 2,530 16,454 14,415 1 3 16 63 64
New York City 993 1,186 2,144 31,788 29,326 — 1 5 27 39
Pennsylvania 560 865 1,089 22,935 21,766 15 9 19 201 178
E.N. Central 910 3,409 4,413 73,093 101,723 17 28 73 610 650
Illinois — 712 1,322 9,334 30,974 — 3 8 71 65
Indiana — 296 602 6,194 11,876 — 4 11 76 128
Michigan 596 888 1,417 24,475 23,730 6 6 11 137 115
Ohio 136 966 1,077 23,026 24,447 7 7 16 179 178
Wisconsin 178 402 494 10,064 10,696 4 8 39 147 164
W.N. Central 225 1,313 1,711 31,707 35,064 12 20 59 402 375
Iowa 15 181 299 4,929 4,925 1 4 13 90 88
Kansas — 193 571 4,554 4,816 1 2 6 47 41
Minnesota — 271 337 6,508 7,311 — 5 31 97 77
Missouri 169 493 638 12,399 13,037 5 3 12 77 71
Nebraska† — 95 237 2,322 2,623 5 2 9 53 41
North Dakota 41 34 93 995 840 — 0 18 11 6
South Dakota — 46 82 — 1,512 — 2 10 27 51
S. Atlantic 2,507 3,791 5,681 87,283 129,320 17 18 50 433 439
Delaware 115 87 156 2,169 2,417 — 0 2 2 1
District of Columbia — 108 178 2,291 3,623 — 0 1 2 4
Florida 557 1,405 1,669 36,005 37,317 12 8 24 179 139
Georgia 5 368 1,323 4,902 20,841 3 6 31 152 179
Maryland† 564 452 1,031 11,169 11,089 — 1 3 13 22
North Carolina — 523 908 — 22,147 — 1 11 11 38
South Carolina† 679 522 729 13,750 14,171 1 1 7 24 23
Virginia† 526 592 924 15,209 15,773 1 2 7 44 28
West Virginia 61 67 137 1,788 1,942 — 0 2 6 5
E.S. Central 1,296 1,761 2,321 42,030 46,568 — 4 10 86 80
Alabama† — 473 652 11,515 13,892 — 1 5 34 27
Kentucky 467 328 642 8,012 5,677 — 1 4 26 20
Mississippi 367 424 784 9,142 12,043 — 0 3 6 6
Tennessee† 462 564 734 13,361 14,956 — 1 5 20 27
W.S. Central 530 2,907 4,578 71,605 82,455 4 8 40 144 148
Arkansas† 304 232 402 4,127 7,276 — 1 5 17 15
Louisiana — 311 1,055 2,922 15,145 — 1 6 17 16
Oklahoma 226 261 1,564 7,469 6,598 3 2 9 32 35
Texas† — 2,065 3,213 57,087 53,436 1 5 30 78 82
Mountain 512 1,522 2,118 34,277 36,376 7 9 25 207 213
Arizona — 471 713 9,605 12,859 — 0 3 14 20
Colorado 318 400 709 9,463 6,839 3 2 10 57 57
Idaho† — 66 192 1,522 1,780 2 2 7 40 26
Montana† 22 58 77 1,498 1,549 — 1 4 26 17
Nevada† 133 177 478 4,928 4,974 1 0 2 7 7
New Mexico† — 163 453 3,304 4,229 — 2 8 31 61
Utah 39 117 175 3,062 3,168 1 1 4 24 11
Wyoming† — 36 70 895 978 — 0 2 8 14
Pacific 960 3,467 5,350 83,101 96,236 9 12 27 255 298
Alaska — 105 146 2,828 2,652 — 0 1 2 2
California 712 2,713 4,406 66,684 73,868 3 8 20 151 163
Hawaii — 113 159 2,646 3,116 — 0 0 — 1
Oregon — 162 468 1,367 5,487 4 2 10 64 94
Washington 248 391 638 9,576 11,113 2 1 8 38 38
American Samoa — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam — 4 27 88 221 — 0 0 — —
Puerto Rico — 99 329 2,469 4,021 N 0 0 N N
U.S. Virgin Islands — 8 15 132 288 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 3, 2010, and July 4, 2009 (26th week)*
Dengue Virus Infection
Reporting area
Dengue Fever† Dengue Hemorrhagic Fever§
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States — 0 8 69 NN — 0 1 1 NN
New England — 0 1 1 NN — 0 0 — NN
Connecticut — 0 0 — NN — 0 0 — NN
Maine¶ — 0 1 1 NN — 0 0 — NN
Massachusetts — 0 0 — NN — 0 0 — NN
New Hampshire — 0 0 — NN — 0 0 — NN
Rhode Island¶ — 0 0 — NN — 0 0 — NN
Vermont¶ — 0 0 — NN — 0 0 — NN
Mid. Atlantic — 0 4 24 NN — 0 0 — NN
New Jersey — 0 0 — NN — 0 0 — NN
New York (Upstate) — 0 0 — NN — 0 0 — NN
New York City — 0 4 20 NN — 0 0 — NN
Pennsylvania — 0 2 4 NN — 0 0 — NN
E.N. Central — 0 2 5 NN — 0 0 — NN
Illinois — 0 0 — NN — 0 0 — NN
Indiana — 0 0 — NN — 0 0 — NN
Michigan — 0 0 — NN — 0 0 — NN
Ohio — 0 2 5 NN — 0 0 — NN
Wisconsin — 0 0 — NN — 0 0 — NN
W.N. Central — 0 0 — NN — 0 0 — NN
Iowa — 0 0 — NN — 0 0 — NN
Kansas — 0 0 — NN — 0 0 — NN
Minnesota — 0 0 — NN — 0 0 — NN
Missouri — 0 0 — NN — 0 0 — NN
Nebraska¶ — 0 0 — NN — 0 0 — NN
North Dakota — 0 0 — NN — 0 0 — NN
South Dakota — 0 0 — NN — 0 0 — NN
S. Atlantic — 0 5 30 NN — 0 1 1 NN
Delaware — 0 0 — NN — 0 0 — NN
District of Columbia — 0 0 — NN — 0 0 — NN
Florida — 0 5 25 NN — 0 1 1 NN
Georgia — 0 2 3 NN — 0 0 — NN
Maryland¶ — 0 0 — NN — 0 0 — NN
North Carolina — 0 0 — NN — 0 0 — NN
South Carolina¶ — 0 1 2 NN — 0 0 — NN
Virginia¶ — 0 0 — NN — 0 0 — NN
West Virginia — 0 0 — NN — 0 0 — NN
E.S. Central — 0 0 — NN — 0 0 — NN
Alabama¶ — 0 0 — NN — 0 0 — NN
Kentucky — 0 0 — NN — 0 0 — NN
Mississippi — 0 0 — NN — 0 0 — NN
Tennessee¶ — 0 0 — NN — 0 0 — NN
W.S. Central — 0 0 — NN — 0 0 — NN
Arkansas¶ — 0 0 — NN — 0 0 — NN
Louisiana — 0 0 — NN — 0 0 — NN
Oklahoma — 0 0 — NN — 0 0 — NN
Texas¶ — 0 0 — NN — 0 0 — NN
Mountain — 0 1 2 NN — 0 0 — NN
Arizona — 0 0 — NN — 0 0 — NN
Colorado — 0 0 — NN — 0 0 — NN
Idaho¶ — 0 0 — NN — 0 0 — NN
Montana¶ — 0 0 — NN — 0 0 — NN
Nevada¶ — 0 1 1 NN — 0 0 — NN
New Mexico¶ — 0 1 1 NN — 0 0 — NN
Utah — 0 0 — NN — 0 0 — NN
Wyoming¶ — 0 0 — NN — 0 0 — NN
Pacific — 0 2 7 NN — 0 0 — NN
Alaska — 0 0 — NN — 0 0 — NN
California — 0 1 4 NN — 0 0 — NN
Hawaii — 0 0 — NN — 0 0 — NN
Oregon — 0 0 — NN — 0 0 — NN
Washington — 0 2 3 NN — 0 0 — NN
American Samoa — 0 0 — NN — 0 0 — NN
C.N.M.I. — — — — NN — — — — NN
Guam — 0 0 — NN — 0 0 — NN
Puerto Rico — 0 82 942 NN — 0 3 22 NN
U.S. Virgin Islands — 0 0 — NN — 0 0 — NN
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Dengue Fever includes cases that meet criteria for Dengue Fever with hemorrhage.
§ DHF includes cases that meet criteria for dengue shock syndrome (DSS), a more severe form of DHF.
¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 3, 2010, and July 4, 2009 (26th week)*
Ehrlichiosis/Anaplasmosis†
Reporting area
Ehrlichia chaffeensis Anaplasma phagocytophilum Undetermined
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 7 9 176 158 316 11 13 309 134 350 1 1 35 19 74
New England — 0 6 4 18 — 2 22 16 107 — 0 1 2 2
Connecticut — 0 0 — — — 0 13 — 1 — 0 0 — —
Maine§ — 0 1 3 2 — 0 2 7 10 — 0 0 — —
Massachusetts — 0 3 — 5 — 0 11 — 64 — 0 0 — —
New Hampshire — 0 1 1 3 — 0 3 6 12 — 0 1 2 1
Rhode Island§ — 0 4 — 8 — 0 20 3 20 — 0 0 — 1
Vermont§ — 0 1 — — — 0 0 — — — 0 0 — —
Mid. Atlantic — 1 15 13 62 10 3 27 52 98 — 0 4 1 20
New Jersey — 0 8 — 40 — 0 6 1 39 — 0 0 — —
New York (Upstate) — 1 15 8 12 10 2 20 51 55 — 0 2 1 1
New York City — 0 2 4 4 — 0 1 — 3 — 0 0 — 1
Pennsylvania — 0 5 1 6 — 0 1 — 1 — 0 3 — 18
E.N. Central — 0 7 5 50 1 3 22 46 139 — 0 6 5 35
Illinois — 0 4 2 25 — 0 1 — 3 — 0 0 — 3
Indiana — 0 0 — — — 0 0 — — — 0 3 4 20
Michigan — 0 1 — 1 — 0 0 — — — 0 0 — —
Ohio — 0 2 — 3 — 0 0 — 1 — 0 1 — —
Wisconsin — 0 3 3 21 1 3 22 46 135 — 0 3 1 12
W.N. Central 2 2 23 47 62 — 0 261 2 — 1 0 30 7 5
Iowa — 0 0 — — — 0 0 — — — 0 0 — —
Kansas — 0 1 2 4 — 0 1 — — — 0 0 — —
Minnesota — 0 6 — — — 0 261 — — — 0 30 — 2
Missouri 2 1 22 44 58 — 0 2 2 — 1 0 4 7 3
Nebraska§ — 0 1 1 — — 0 1 — — — 0 0 — —
North Dakota — 0 0 — — — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — — — 0 0 — —
S. Atlantic 4 3 14 56 64 — 0 4 16 4 — 0 2 — —
Delaware — 0 3 9 8 — 0 1 2 1 — 0 0 — —
District of Columbia — 0 0 — — — 0 0 — — — 0 0 — —
Florida 1 0 2 6 6 — 0 1 1 — — 0 0 — —
Georgia — 0 2 6 12 — 0 1 1 1 — 0 0 — —
Maryland§ 1 0 3 8 23 — 0 2 7 2 — 0 0 — —
North Carolina — 0 3 7 — — 0 1 1 — — 0 0 — —
South Carolina§ — 0 2 2 6 — 0 0 — — — 0 0 — —
Virginia§ 2 1 13 18 9 — 0 2 4 — — 0 2 — —
West Virginia — 0 1 — — — 0 0 — — — 0 1 — —
E.S. Central 1 1 11 25 45 — 0 1 2 1 — 0 5 4 12
Alabama§ — 0 3 4 1 — 0 1 1 — — 0 0 — —
Kentucky — 0 2 2 4 — 0 0 — — — 0 0 — —
Mississippi — 0 2 — 5 — 0 0 — — — 0 0 — —
Tennessee§ 1 1 10 19 35 — 0 1 1 1 — 0 5 4 12
W.S. Central — 0 141 8 13 — 0 23 — 1 — 0 1 — —
Arkansas§ — 0 34 — 2 — 0 6 — — — 0 0 — —
Louisiana — 0 0 — — — 0 0 — — — 0 0 — —
Oklahoma — 0 105 7 11 — 0 16 — 1 — 0 0 — —
Texas§ — 0 2 1 — — 0 1 — — — 0 1 — —
Mountain — 0 0 — — — 0 0 — — — 0 1 — —
Arizona — 0 0 — — — 0 0 — — — 0 1 — —
Colorado — 0 0 — — — 0 0 — — — 0 0 — —
Idaho§ — 0 0 — — — 0 0 — — — 0 0 — —
Montana§ — 0 0 — — — 0 0 — — — 0 0 — —
Nevada§ — 0 0 — — — 0 0 — — — 0 0 — —
New Mexico§ — 0 0 — — — 0 0 — — — 0 0 — —
Utah — 0 0 — — — 0 0 — — — 0 0 — —
Wyoming§ — 0 0 — — — 0 0 — — — 0 0 — —
Pacific — 0 1 — 2 — 0 1 — — — 0 1 — —
Alaska — 0 0 — — — 0 0 — — — 0 0 — —
California — 0 1 — 2 — 0 1 — — — 0 1 — —
Hawaii — 0 0 — — — 0 0 — — — 0 0 — —
Oregon — 0 0 — — — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — — — 0 0 — —
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Cumulative total E. ewingii cases reported for year 2010 = 2.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 3, 2010, and July 4, 2009 (26th week)*
Reporting area
Giardiasis Gonorrhea
Haemophilus influenzae, invasive†  
All ages, all serotypes
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 200 345 662 7,593 7,993 2,351 5,171 6,656 118,083 150,824 27 52 171 1,449 1,608
New England 3 24 65 362 648 48 92 197 2,422 2,416 3 2 21 41 103
Connecticut — 5 15 112 129 — 45 170 1,044 1,123 3 0 15 20 28
Maine§ 1 4 13 93 88 1 3 11 98 71 — 0 2 6 12
Massachusetts — 8 36 — 274 45 40 72 1,044 967 — 0 8 — 51
New Hampshire 1 3 11 62 70 2 2 7 75 53 — 0 2 7 6
Rhode Island§ — 1 7 19 30 — 6 13 134 179 — 0 2 4 2
Vermont§ 1 4 14 76 57 — 1 17 27 23 — 0 1 4 4
Mid. Atlantic 34 61 112 1,324 1,511 493 641 941 16,272 14,935 8 11 34 309 292
New Jersey — 7 15 113 211 90 93 134 2,305 2,314 — 2 7 41 67
New York (Upstate) 26 24 84 506 550 93 104 422 2,604 2,526 4 3 20 87 69
New York City — 16 26 372 405 179 215 394 5,849 5,349 — 2 6 61 33
Pennsylvania 8 15 37 333 345 131 209 277 5,514 4,746 4 4 9 120 123
E.N. Central 27 52 92 1,194 1,258 283 1,033 1,536 20,116 32,273 3 8 19 244 263
Illinois — 12 22 227 276 — 232 441 2,305 10,329 — 2 9 59 100
Indiana — 6 14 115 115 — 77 183 1,662 3,865 — 1 6 43 49
Michigan 6 13 25 296 296 200 248 502 6,867 7,705 — 0 4 19 12
Ohio 18 16 28 405 377 39 319 372 7,107 7,720 3 2 6 63 58
Wisconsin 3 8 23 151 194 44 91 192 2,175 2,654 — 2 5 60 44
W.N. Central 18 27 165 668 674 71 267 367 6,354 7,492 — 3 24 90 82
Iowa 8 5 13 130 137 3 31 55 779 847 — 0 1 1 —
Kansas 3 4 14 101 62 — 40 83 917 1,277 — 0 2 8 11
Minnesota — 0 135 136 137 — 41 64 927 1,171 — 0 17 24 18
Missouri 2 9 27 170 215 60 122 172 3,148 3,295 — 1 6 40 35
Nebraska§ 5 3 9 91 79 — 22 54 511 659 — 0 3 9 13
North Dakota — 0 8 11 7 8 2 11 72 57 — 0 4 8 5
South Dakota — 1 10 29 37 — 3 16 — 186 — 0 0 — —
S. Atlantic 60 73 143 1,830 1,703 665 1,108 1,656 24,299 37,867 6 13 27 359 450
Delaware — 0 3 12 15 27 19 37 486 434 — 0 1 5 3
District of Columbia — 1 4 16 37 — 42 86 863 1,394 — 0 1 1 1
Florida 33 39 87 946 891 169 381 482 9,616 10,689 2 3 9 104 146
Georgia 16 13 52 421 356 — 132 494 1,765 7,083 1 3 9 91 88
Maryland§ 1 6 12 141 132 150 128 237 3,210 2,967 1 1 6 29 53
North Carolina N 0 0 N N — 143 331 — 7,380 — 1 6 20 56
South Carolina§ 4 2 7 56 43 206 159 217 4,087 4,253 2 2 7 54 37
Virginia§ 6 8 36 222 209 109 164 271 4,048 3,390 — 2 4 44 48
West Virginia — 1 5 16 20 4 8 19 224 277 — 0 5 11 18
E.S. Central — 7 22 116 178 372 481 689 11,421 13,260 — 3 12 95 107
Alabama§ — 4 13 69 85 — 138 187 3,376 3,795 — 0 3 15 28
Kentucky N 0 0 N N 132 88 156 2,021 1,655 — 0 2 14 15
Mississippi N 0 0 N N 112 125 219 2,544 3,729 — 0 2 9 7
Tennessee§ — 3 18 47 93 128 145 206 3,480 4,081 — 2 10 57 57
W.S. Central 9 9 18 163 199 160 819 1,230 18,743 23,932 4 2 20 77 75
Arkansas§ 4 2 9 50 59 86 74 139 1,196 2,202 1 0 3 12 15
Louisiana 1 3 10 63 85 — 106 343 910 4,920 — 0 3 15 13
Oklahoma 4 3 10 50 55 74 80 381 2,092 2,150 3 1 15 44 44
Texas§ N 0 0 N N — 565 965 14,545 14,660 — 0 2 6 3
Mountain 15 33 64 692 647 40 168 266 3,957 4,442 2 5 14 176 142
Arizona — 3 7 65 91 — 62 109 1,121 1,436 1 2 10 69 49
Colorado 13 12 26 334 182 18 50 127 1,270 1,376 — 1 6 47 40
Idaho§ 1 4 10 96 64 — 2 8 38 47 1 0 2 9 2
Montana§ — 3 11 54 47 1 2 6 58 40 — 0 1 2 1
Nevada§ 1 1 11 27 46 20 27 94 881 859 — 0 2 5 11
New Mexico§ — 1 8 32 57 — 20 41 405 502 — 1 5 24 18
Utah — 4 13 66 131 1 7 15 168 150 — 0 4 15 19
Wyoming§ — 1 5 18 29 — 1 7 16 32 — 0 2 5 2
Pacific 34 54 133 1,244 1,175 219 561 663 14,499 14,207 1 2 9 58 94
Alaska — 2 7 40 39 — 23 36 634 426 — 0 2 11 9
California 18 34 61 793 824 181 460 556 12,268 11,707 — 0 2 6 34
Hawaii — 0 3 3 11 — 11 24 300 326 — 0 2 — 20
Oregon 8 9 17 228 159 — 11 43 106 563 1 1 5 38 28
Washington 8 9 75 180 142 38 43 84 1,191 1,185 — 0 4 3 3
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 2 1 1 — 0 3 8 12 — 0 0 — —
Puerto Rico — 1 10 11 81 — 4 24 117 116 — 0 1 1 2
U.S. Virgin Islands — 0 0 — — — 1 4 25 82 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 3, 2010, and July 4, 2009 (26th week)*

















Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 14 30 68 649 974 30 58 203 1,362 1,657 9 14 43 364 389
New England 1 1 5 22 52 — 1 3 22 29 — 1 5 11 31
Connecticut 1 0 2 14 12 — 0 2 6 8 — 1 4 11 23
Maine† — 0 1 4 1 — 0 2 9 6 — 0 1 — —
Massachusetts — 0 4 — 29 — 0 2 — 12 — 0 1 — 7
New Hampshire — 0 1 — 5 — 0 2 5 3 — 0 0 — —
Rhode Island† — 0 4 4 3 — 0 0 — U — 0 0 — U
Vermont† — 0 0 — 2 — 0 1 2 — — 0 0 — 1
Mid. Atlantic 2 4 10 92 139 2 5 10 140 196 2 2 5 53 48
New Jersey — 0 4 10 39 — 1 4 32 63 — 0 2 5 2
New York (Upstate) — 1 3 26 25 2 1 6 27 34 1 1 3 30 25
New York City — 1 5 29 40 — 1 4 43 34 — 0 1 — 1
Pennsylvania 2 1 6 27 35 — 1 5 38 65 1 0 3 18 20
E.N. Central 2 4 19 88 151 2 8 15 208 237 — 2 6 75 51
Illinois — 1 13 16 62 — 2 6 39 55 — 0 1 1 3
Indiana — 0 4 8 13 — 1 5 25 40 — 0 2 12 10
Michigan — 1 4 27 36 1 2 6 55 71 — 1 6 55 16
Ohio 2 0 4 17 24 1 2 6 61 59 — 0 3 5 19
Wisconsin — 0 3 20 16 — 1 3 28 12 — 0 1 2 3
W.N. Central — 1 10 24 57 1 3 15 66 63 — 0 11 12 6
Iowa — 0 3 4 17 — 1 3 10 15 — 0 4 1 3
Kansas — 0 2 7 6 — 0 2 4 4 — 0 0 — 1
Minnesota — 0 8 1 12 — 0 13 2 10 — 0 9 3 —
Missouri — 0 3 11 10 1 1 5 41 23 — 0 1 7 —
Nebraska† — 0 3 1 10 — 0 2 9 10 — 0 1 1 2
North Dakota — 0 1 — — — 0 0 — — — 0 1 — —
South Dakota — 0 1 — 2 — 0 1 — 1 — 0 1 — —
S. Atlantic 5 7 14 146 214 11 16 39 390 446 3 3 7 69 100
Delaware — 0 1 5 3 — 1 2 16 18 U 0 0 U U
District of Columbia — 0 1 1 1 — 0 2 2 7 — 0 1 2 —
Florida 3 3 8 61 96 5 5 11 153 156 1 1 4 25 20
Georgia — 1 3 17 23 3 3 7 78 71 — 0 2 6 24
Maryland† — 0 4 11 21 1 1 6 28 44 1 0 2 13 12
North Carolina — 0 3 11 33 — 0 4 4 63 — 0 4 9 20
South Carolina† — 1 4 21 21 1 1 4 27 23 — 0 0 — 1
Virginia† 2 1 3 18 16 1 2 14 50 41 1 0 2 8 7
West Virginia — 0 2 1 — — 0 19 32 23 — 0 3 6 16
E.S. Central — 1 3 18 23 2 6 13 142 168 1 2 7 63 54
Alabama† — 0 1 4 6 — 1 5 29 49 — 0 2 2 5
Kentucky — 0 2 9 4 — 2 6 45 42 — 1 5 43 33
Mississippi — 0 1 — 6 — 0 3 14 12 — 0 0 — U
Tennessee† — 0 2 5 7 2 2 6 54 65 1 0 4 18 16
W.S. Central 1 3 19 71 91 8 9 109 201 280 1 1 14 27 25
Arkansas† — 0 3 — 5 — 1 4 25 37 — 0 1 — 1
Louisiana — 0 2 6 2 — 1 5 20 31 — 0 1 3 4
Oklahoma — 0 3 — 1 5 1 19 35 50 — 0 12 13 4
Texas† 1 2 18 65 83 3 5 87 121 162 1 0 4 11 16
Mountain — 3 8 76 73 — 2 6 52 74 — 1 4 21 30
Arizona — 1 5 39 31 — 0 2 18 29 — 0 0 — U
Colorado — 1 4 12 21 — 0 2 2 13 — 0 2 2 18
Idaho† — 0 2 5 1 — 0 2 4 4 — 0 2 7 2
Montana† — 0 1 4 4 — 0 1 1 — — 0 0 — 1
Nevada† — 0 2 6 7 — 0 3 21 15 — 0 1 2 2
New Mexico† — 0 1 3 6 — 0 1 2 5 — 0 2 6 5
Utah — 0 2 4 3 — 0 1 4 4 — 0 1 4 2
Wyoming† — 0 3 3 — — 0 1 — 4 — 0 0 — —
Pacific 3 5 16 112 174 4 6 20 141 164 2 1 6 33 44
Alaska — 0 0 — 2 — 0 1 1 2 — 0 2 — U
California 3 4 15 90 130 1 4 16 97 117 1 0 4 14 22
Hawaii — 0 2 — 7 — 0 1 — 4 — 0 0 — U
Oregon — 0 2 11 9 — 1 4 23 23 — 0 3 8 11
Washington — 0 2 11 26 3 0 4 20 18 1 0 6 11 11
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 6 12 4 — 0 6 22 37 — 0 6 21 26
Puerto Rico — 0 2 2 18 — 0 5 8 19 — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 3, 2010, and July 4, 2009 (26th week)*
Reporting area
Legionellosis Lyme disease Malaria
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 60 58 174 1,074 1,165 374 393 2,345 7,164 13,965 13 25 87 494 578
New England — 2 18 25 62 40 93 857 1,392 5,368 — 1 4 7 27
Connecticut — 1 4 12 19 — 37 295 687 1,964 — 0 1 1 4
Maine† — 0 3 3 — 24 13 76 201 161 — 0 1 3 1
Massachusetts — 0 9 — 37 — 16 401 — 2,396 — 0 3 — 16
New Hampshire — 0 3 3 3 1 21 95 409 672 — 0 1 1 2
Rhode Island† — 0 4 5 2 — 1 29 10 56 — 0 1 1 2
Vermont† — 0 1 2 1 15 4 45 85 119 — 0 1 1 2
Mid. Atlantic 19 15 73 247 381 255 187 999 3,820 5,527 — 7 17 143 168
New Jersey — 1 14 4 87 5 43 430 933 2,462 — 0 5 1 46
New York (Upstate) 12 5 29 89 87 129 56 577 943 1,092 — 1 4 33 24
New York City — 2 19 47 78 — 3 58 3 392 — 3 12 83 70
Pennsylvania 7 6 23 107 129 121 72 475 1,941 1,581 — 1 4 26 28
E.N. Central 14 11 41 217 208 3 23 258 510 1,201 1 2 12 52 73
Illinois — 1 11 8 29 — 1 12 13 60 — 1 7 19 34
Indiana 1 1 6 39 25 — 1 6 20 33 — 0 4 7 9
Michigan 2 2 13 38 40 — 1 9 20 16 — 0 3 6 11
Ohio 11 5 17 108 86 1 1 5 9 10 1 0 6 19 15
Wisconsin — 1 6 24 28 2 18 239 448 1,082 — 0 2 1 4
W.N. Central 2 2 19 51 43 — 2 1,395 27 106 — 1 11 24 27
Iowa — 0 3 4 11 — 0 14 16 66 — 0 1 6 5
Kansas — 0 2 5 4 — 0 2 5 12 — 0 1 3 2
Minnesota — 0 16 15 5 — 0 1,380 — 26 — 0 11 3 12
Missouri 2 1 5 18 17 — 0 1 3 1 — 0 1 4 5
Nebraska† — 0 2 4 5 — 0 1 3 — — 0 2 8 2
North Dakota — 0 1 3 1 — 0 15 — — — 0 1 — —
South Dakota — 0 1 2 — — 0 0 — 1 — 0 0 — 1
S. Atlantic 13 11 24 227 224 75 62 258 1,244 1,621 10 6 15 134 166
Delaware — 0 5 8 8 11 12 65 297 393 — 0 1 2 1
District of Columbia — 0 4 12 13 — 0 4 8 32 — 0 3 6 6
Florida 8 4 10 86 70 6 2 11 32 17 3 2 7 55 41
Georgia — 1 4 23 25 — 0 6 4 27 — 0 6 3 36
Maryland† 5 3 12 52 56 40 27 134 569 793 2 1 13 28 42
North Carolina — 0 5 2 27 — 0 6 12 56 — 0 3 5 18
South Carolina† — 0 2 5 3 — 1 3 17 17 — 0 1 3 1
Virginia† — 1 6 34 22 18 14 79 290 253 5 1 5 32 20
West Virginia — 0 3 5 — — 0 33 15 33 — 0 2 — 1
E.S. Central 3 2 12 58 55 1 1 4 22 11 — 0 4 11 20
Alabama† — 0 2 7 9 — 0 1 — 1 — 0 3 2 6
Kentucky — 0 3 10 23 — 0 1 1 1 — 0 3 3 5
Mississippi — 0 2 5 2 — 0 0 — — — 0 1 — 2
Tennessee† 3 1 9 36 21 1 1 4 21 9 — 0 1 6 7
W.S. Central — 2 14 41 52 — 3 44 31 51 — 1 31 47 20
Arkansas† — 0 2 8 4 — 0 0 — — — 0 1 1 2
Louisiana — 0 3 1 5 — 0 0 — — — 0 1 — 4
Oklahoma — 0 4 6 3 — 0 2 — — — 0 1 3 —
Texas† — 1 10 26 40 — 3 42 31 51 — 1 30 43 14
Mountain 3 3 8 71 57 — 0 4 6 24 — 1 6 20 17
Arizona 3 1 4 22 23 — 0 1 1 1 — 0 2 11 2
Colorado — 1 5 17 7 — 0 1 1 — — 0 3 3 11
Idaho† — 0 2 — 1 — 0 3 1 6 — 0 1 — 1
Montana† — 0 1 4 4 — 0 1 — 1 — 0 3 1 1
Nevada† — 0 2 15 6 — 0 2 — 8 — 0 1 2 —
New Mexico† — 0 2 2 1 — 0 1 1 1 — 0 0 — —
Utah — 0 3 9 14 — 0 1 2 6 — 0 1 3 2
Wyoming† — 0 2 2 1 — 0 1 — 1 — 0 0 — —
Pacific 6 4 19 137 83 — 5 10 112 56 2 3 19 56 60
Alaska — 0 0 — 1 — 0 1 1 3 — 0 1 2 2
California 3 3 19 119 63 — 3 9 75 31 1 1 13 34 45
Hawaii — 0 1 1 1 N 0 0 N N — 0 0 — 1
Oregon 1 0 3 6 7 — 1 4 32 19 — 0 1 5 7
Washington 2 0 4 11 11 — 0 3 4 3 1 0 5 15 5
American Samoa — 0 0 — — N 0 0 N N — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 1 — — N 0 0 N N — 0 2 1 1
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 3, 2010, and July 4, 2009 (26th week)*
Reporting area
Meningococcal disease, invasive† 
All groups Pertussis Rabies, animal
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 9 16 43 406 550 136 273 1,750 5,999 6,986 31 66 147 1,320 2,581
New England 1 0 2 7 18 — 5 21 46 347 2 5 24 118 169
Connecticut 1 0 2 1 2 — 1 5 20 19 — 1 22 59 73
Maine§ — 0 1 2 2 — 0 4 12 60 — 1 4 28 28
Massachusetts — 0 1 — 10 — 3 12 — 205 — 0 0 — —
New Hampshire — 0 1 — 1 — 0 4 6 44 — 0 2 3 19
Rhode Island§ — 0 1 — 2 — 0 8 5 11 — 0 5 3 20
Vermont§ — 0 1 4 1 — 0 1 3 8 2 1 5 25 29
Mid. Atlantic 1 1 4 37 62 35 20 41 412 574 8 11 26 343 294
New Jersey — 0 2 8 11 — 3 10 46 127 — 0 0 — —
New York (Upstate) 1 0 3 9 12 27 6 27 174 91 8 9 22 239 192
New York City — 0 2 8 12 — 0 11 24 49 — 2 12 104 2
Pennsylvania — 0 2 12 27 8 8 22 168 307 — 0 0 — 100
E.N. Central — 2 8 68 103 36 61 108 1,483 1,410 5 2 19 79 83
Illinois — 0 4 11 26 1 11 29 241 335 3 1 9 33 27
Indiana — 0 3 15 23 — 7 19 150 163 — 0 5 — 17
Michigan — 0 2 10 17 8 19 41 426 294 — 1 6 27 24
Ohio — 1 2 18 23 26 18 46 579 535 2 0 5 19 15
Wisconsin — 0 2 14 14 1 3 12 87 83 — 0 0 — —
W.N. Central 1 2 6 32 40 6 25 627 440 1,085 7 6 18 124 191
Iowa — 0 3 6 6 — 4 21 155 125 — 0 4 7 17
Kansas — 0 2 4 7 — 3 12 63 120 1 1 4 33 49
Minnesota — 0 2 2 8 — 0 601 6 194 — 1 9 15 20
Missouri — 0 3 14 13 1 11 35 146 545 3 1 5 33 20
Nebraska§ 1 0 2 5 4 5 2 6 51 88 3 1 6 29 52
North Dakota — 0 1 1 — — 0 12 5 2 — 0 7 7 4
South Dakota — 0 2 — 2 — 1 6 14 11 — 0 4 — 29
S. Atlantic 1 2 7 77 108 7 22 63 518 765 2 27 58 489 1,150
Delaware — 0 1 1 2 — 0 3 5 6 — 0 0 — —
District of Columbia — 0 0 — — — 0 1 3 3 — 0 0 — —
Florida 1 1 5 39 32 5 6 28 137 252 — 0 22 52 161
Georgia — 0 1 6 20 — 3 8 87 134 — 4 14 — 217
Maryland§ — 0 1 4 5 1 2 8 48 67 — 6 15 158 183
North Carolina — 0 2 5 27 — 0 6 — 110 — 3 17 — 253
South Carolina§ — 0 1 7 8 1 5 23 164 102 — 0 0 — —
Virginia§ — 0 2 13 10 — 4 15 65 85 — 10 26 240 277
West Virginia — 0 2 2 4 — 0 6 9 6 2 2 6 39 59
E.S. Central — 0 4 19 19 2 14 31 355 402 1 2 7 56 89
Alabama§ — 0 2 4 5 — 5 16 109 149 1 0 4 24 —
Kentucky — 0 2 8 4 — 4 15 122 109 — 0 2 3 29
Mississippi — 0 1 2 2 — 1 6 26 42 — 0 1 — 1
Tennessee§ — 0 2 5 8 2 4 10 98 102 — 1 6 29 59
W.S. Central 2 1 9 48 45 14 67 753 1,364 1,356 1 4 40 19 440
Arkansas§ — 0 2 5 5 — 5 29 50 142 1 0 10 13 27
Louisiana — 0 3 8 10 — 1 7 16 93 — 0 0 — —
Oklahoma 1 0 7 13 3 2 0 41 14 15 — 0 15 6 4
Texas§ 1 1 7 22 27 12 60 681 1,284 1,106 — 3 30 — 409
Mountain — 1 5 34 43 13 19 41 498 508 — 1 8 21 51
Arizona — 0 2 9 8 — 7 14 192 101 — 0 5 — —
Colorado — 0 3 11 13 5 2 13 59 139 — 0 0 — —
Idaho§ — 0 1 5 6 1 2 19 79 47 — 0 2 1 —
Montana§ — 0 1 1 5 — 1 8 31 12 — 0 4 2 15
Nevada§ — 0 1 5 3 7 0 6 15 7 — 0 1 2 1
New Mexico§ — 0 1 2 3 — 1 6 33 33 — 0 3 5 15
Utah — 0 1 1 1 — 3 9 86 149 — 0 2 — 3
Wyoming§ — 0 1 — 4 — 0 1 3 20 — 0 3 11 17
Pacific 3 3 16 84 112 23 32 186 883 539 5 3 12 71 114
Alaska — 0 2 1 3 — 0 6 12 29 — 0 2 11 9
California 2 2 13 55 72 10 20 162 638 233 4 3 11 54 102
Hawaii — 0 2 — 3 — 0 4 — 19 — 0 0 — —
Oregon 1 1 5 19 25 1 6 14 150 115 1 0 2 6 3
Washington — 0 7 9 9 12 4 24 83 143 — 0 0 — —
American Samoa — 0 0 — — — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 2 — — — 0 0 — —
Puerto Rico — 0 1 — — — 0 0 — 1 1 1 3 23 23
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 3, 2010, and July 4, 2009 (26th week)*
Reporting area
Salmonellosis Shiga toxin-producing E. coli (STEC)† Shigellosis
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 546 810 1,521 14,955 19,045 75 71 195 1,385 1,855 150 260 523 6,113 8,046
New England 4 20 201 367 1,307 — 2 30 44 141 — 2 28 37 122
Connecticut — 0 196 196 430 — 0 25 25 67 — 0 26 26 43
Maine§ 1 2 7 45 57 — 0 2 4 9 — 0 2 3 2
Massachusetts — 12 47 — 530 — 0 6 — 40 — 1 27 — 64
New Hampshire 1 3 9 69 179 — 0 3 10 16 — 0 5 3 2
Rhode Island§ — 2 11 33 73 — 0 26 — — — 0 7 4 8
Vermont§ 2 1 5 24 38 — 0 3 5 9 — 0 1 1 3
Mid. Atlantic 60 91 208 1,933 2,216 9 7 24 158 182 14 35 90 787 1,534
New Jersey — 15 47 245 465 — 1 5 16 54 — 7 23 128 333
New York (Upstate) 26 24 78 513 490 5 3 15 71 44 3 4 19 82 98
New York City — 24 46 473 501 — 1 4 16 36 — 7 15 141 224
Pennsylvania 34 29 67 702 760 4 2 8 55 48 11 19 63 436 879
E.N. Central 40 76 168 1,759 2,471 9 9 29 195 340 14 27 234 907 1,531
Illinois — 24 52 564 696 — 1 6 12 95 — 9 227 525 356
Indiana — 8 31 58 283 — 1 9 16 37 — 1 5 18 41
Michigan 6 15 34 337 482 3 2 16 72 60 — 3 10 101 135
Ohio 33 25 52 632 681 6 2 11 56 56 14 8 46 165 701
Wisconsin 1 9 26 168 329 — 2 11 39 92 — 5 18 98 298
W.N. Central 37 44 94 946 1,254 9 11 41 250 273 31 48 88 1,431 421
Iowa 3 7 16 155 203 — 3 12 49 74 — 0 5 27 42
Kansas 5 6 20 159 170 2 1 5 26 29 6 3 14 136 129
Minnesota — 9 32 179 271 — 2 17 31 61 — 0 6 14 33
Missouri 20 13 29 311 254 4 2 29 104 56 25 44 75 1,237 199
Nebraska§ 9 4 12 89 207 3 1 6 34 39 — 0 3 14 13
North Dakota — 0 39 15 27 — 0 7 — 4 — 0 5 — 3
South Dakota — 2 9 38 122 — 0 12 6 10 — 0 2 3 2
S. Atlantic 207 251 503 4,024 4,638 13 12 23 235 307 31 40 71 895 1,217
Delaware — 2 9 46 36 — 0 2 1 8 — 3 10 33 42
District of Columbia — 2 6 34 46 — 0 1 4 1 — 0 4 16 14
Florida 119 126 277 1,941 1,974 8 3 8 92 82 23 11 30 380 227
Georgia 33 39 105 659 837 — 1 4 24 34 4 12 24 316 327
Maryland§ 18 15 32 330 336 4 1 6 36 38 3 3 17 46 207
North Carolina — 30 90 230 622 — 1 5 4 63 — 2 26 15 233
South Carolina§ 15 19 66 337 302 1 0 3 12 14 1 1 6 33 68
Virginia§ 22 18 68 368 392 — 2 15 56 58 — 3 15 55 94
West Virginia — 3 23 79 93 — 0 5 6 9 — 0 2 1 5
E.S. Central 19 50 118 935 1,120 1 4 10 80 106 1 11 40 336 496
Alabama§ — 14 40 242 323 — 1 4 21 25 — 2 10 50 95
Kentucky — 8 28 191 216 — 1 4 8 34 — 3 28 153 125
Mississippi 1 13 42 218 280 — 0 2 10 6 — 1 4 18 18
Tennessee§ 18 13 33 284 301 1 1 8 41 41 1 5 13 115 258
W.S. Central 50 104 547 1,532 1,985 3 4 68 75 124 41 48 251 1,025 1,575
Arkansas§ 23 10 25 192 228 1 1 5 23 13 1 2 11 24 180
Louisiana 1 17 46 330 415 — 0 3 5 14 2 3 9 101 112
Oklahoma 9 10 46 198 240 2 0 27 6 9 1 7 96 149 110
Texas§ 17 60 477 812 1,102 — 3 41 41 88 37 34 144 751 1,173
Mountain 29 49 133 1,066 1,338 13 7 26 158 222 4 14 43 288 601
Arizona 4 18 50 343 446 1 1 5 33 30 2 9 38 155 434
Colorado 12 11 33 264 282 9 2 11 33 83 1 2 6 47 41
Idaho§ 3 3 10 66 81 2 1 7 23 29 — 0 3 9 3
Montana§ — 2 7 48 62 — 1 7 23 11 — 0 1 4 11
Nevada§ 9 4 14 106 119 1 0 4 12 13 1 1 7 16 32
New Mexico§ — 5 40 96 153 — 1 3 13 19 — 1 6 47 67
Utah — 5 15 125 154 — 1 11 17 35 — 0 4 10 12
Wyoming§ 1 1 9 18 41 — 0 2 4 2 — 0 2 — 1
Pacific 100 116 299 2,393 2,716 18 9 46 190 160 14 21 64 407 549
Alaska — 1 6 41 31 — 0 1 1 1 — 0 2 — 1
California 68 84 227 1,753 2,076 11 4 35 88 96 10 16 51 345 431
Hawaii 8 4 62 20 124 — 0 4 6 3 1 0 4 3 16
Oregon 4 8 49 283 207 — 1 11 29 14 — 1 4 27 25
Washington 20 15 61 296 278 7 3 19 66 46 3 2 9 32 76
American Samoa 1 1 1 2 — — 0 0 — — — 1 1 1 3
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 2 2 5 — 0 0 — — — 0 3 1 3
Puerto Rico 4 7 39 101 260 — 0 0 — — — 0 1 — 7
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 3, 2010, and July 4, 2009 (26th week)*











Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 1 2 8 41 68 12 13 416 336 630
New England — 0 1 — 1 — 0 1 1 8
Connecticut — 0 0 — — — 0 0 — —
Maine§ — 0 0 — — — 0 1 1 4
Massachusetts — 0 0 — 1 — 0 1 — 4
New Hampshire — 0 0 — — — 0 1 — —
Rhode Island§ — 0 0 — — — 0 0 — —
Vermont§ — 0 1 — — — 0 0 — —
Mid. Atlantic — 0 3 10 2 — 1 6 17 49
New Jersey — 0 1 — 1 — 0 3 — 35
New York (Upstate) — 0 1 1 — — 0 3 3 2
New York City — 0 1 2 — — 0 2 8 5
Pennsylvania — 0 2 7 1 — 0 1 6 7
E.N. Central — 0 1 1 5 2 0 5 19 50
Illinois — 0 1 1 — — 0 3 6 34
Indiana — 0 0 — 3 2 0 2 9 5
Michigan — 0 1 — 1 — 0 2 3 —
Ohio — 0 0 — — — 0 4 1 9
Wisconsin — 0 0 — 1 — 0 1 — 2
W.N. Central 1 0 3 6 7 3 2 23 101 113
Iowa — 0 1 — — — 0 1 — 2
Kansas — 0 1 2 1 — 0 0 — —
Minnesota — 0 1 — — — 0 1 — —
Missouri 1 0 1 3 3 3 2 22 100 110
Nebraska§ — 0 2 1 3 — 0 1 1 1
North Dakota — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — —
S. Atlantic — 0 3 13 42 4 3 31 86 206
Delaware — 0 1 1 — — 0 3 5 4
District of Columbia — 0 0 — — — 0 1 — —
Florida — 0 1 1 — — 0 2 8 2
Georgia — 0 3 9 35 — 0 0 — —
Maryland§ — 0 1 1 2 2 0 3 8 30
North Carolina — 0 1 1 3 — 1 23 27 131
South Carolina§ — 0 1 — 2 — 0 1 3 13
Virginia§ — 0 1 — — 2 0 7 35 26
West Virginia — 0 0 — — — 0 1 — —
E.S. Central — 0 2 4 2 2 3 16 95 124
Alabama§ — 0 1 — 1 — 1 7 19 26
Kentucky — 0 1 2 1 — 0 0 — —
Mississippi — 0 0 — — — 0 1 — 8
Tennessee§ — 0 2 2 — 2 2 13 76 90
W.S. Central — 0 3 1 1 1 1 408 13 67
Arkansas§ — 0 1 — — — 0 110 — 43
Louisiana — 0 0 — — — 0 0 — 2
Oklahoma — 0 3 — — 1 0 287 9 10
Texas§ — 0 1 1 1 — 0 11 4 12
Mountain — 0 2 2 7 — 0 3 4 13
Arizona — 0 2 — 2 — 0 2 1 5
Colorado — 0 1 — — — 0 0 — —
Idaho§ — 0 0 — — — 0 1 1 —
Montana§ — 0 1 2 4 — 0 1 1 5
Nevada§ — 0 0 — — — 0 1 — 1
New Mexico§ — 0 0 — — — 0 1 1 1
Utah — 0 0 — — — 0 0 — 1
Wyoming§ — 0 0 — 1 — 0 1 — —
Pacific — 0 2 4 1 — 0 0 — —
Alaska N 0 0 N N N 0 0 N N
California — 0 2 4 1 — 0 0 — —
Hawaii N 0 0 N N N 0 0 N N
Oregon — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — —
American Samoa N 0 0 N N N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam N 0 0 N N N 0 0 N N
Puerto Rico N 0 0 N N N 0 0 N N
U.S. Virgin Islands — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Illnesses with similar clinical presentation that result from Spotted fever group rickettsia infections are reported as Spotted fever rickettsioses. Rocky Mountain spotted fever (RMSF) caused 
by Rickettsia rickettsii, is the most common and well-known spotted fever.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 3, 2010, and July 4, 2009 (26th week)*
Streptococcus pneumoniae,† invasive disease
Reporting area
All ages Age <5 Syphilis, primary and secondary
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 84 152 477 8,681 1,863 12 48 156 1,329 1,369 84 235 413 5,238 6,866
New England 17 4 98 465 30 — 1 24 36 45 9 7 22 223 158
Connecticut 17 0 93 241 — — 0 22 22 — — 1 10 39 32
Maine§ — 1 6 72 8 — 0 2 6 2 — 0 3 14 1
Massachusetts — 0 1 — 2 — 0 3 — 34 8 5 12 140 111
New Hampshire — 0 7 59 — — 0 2 3 6 — 0 1 10 10
Rhode Island§ — 0 7 40 11 — 0 1 2 1 1 0 5 18 4
Vermont§ — 0 6 53 9 — 0 1 3 2 — 0 2 2 —
Mid. Atlantic 4 10 52 733 111 1 7 48 208 172 29 33 47 829 898
New Jersey — 0 8 65 — — 1 4 36 27 1 4 12 116 128
New York (Upstate) 1 3 12 106 44 1 3 19 77 80 1 2 11 52 54
New York City — 2 25 255 4 — 1 24 59 53 22 18 39 476 545
Pennsylvania 3 4 22 307 63 — 0 5 36 12 5 7 14 185 171
E.N. Central 15 22 96 1,740 435 2 8 18 208 226 1 27 44 479 732
Illinois — 0 7 51 — — 1 5 45 36 — 12 21 127 356
Indiana — 6 23 342 174 — 1 6 29 45 — 3 9 58 74
Michigan — 2 26 412 19 — 1 6 49 45 — 4 13 110 118
Ohio 13 13 49 747 242 2 2 6 59 77 — 7 13 164 157
Wisconsin 2 0 22 188 — — 1 4 26 23 1 0 3 20 27
W.N. Central 5 6 182 546 113 — 3 12 99 97 2 5 12 132 150
Iowa — 0 0 — — — 0 0 — — — 0 2 4 13
Kansas 1 1 7 61 43 — 0 2 11 14 — 0 3 10 12
Minnesota — 1 179 287 20 — 1 10 44 32 2 1 5 44 36
Missouri 2 1 9 74 41 — 0 3 27 34 — 3 8 69 82
Nebraska§ 2 1 7 82 — — 0 2 10 6 — 0 1 5 4
North Dakota — 0 11 31 7 — 0 1 2 4 — 0 1 — 3
South Dakota — 0 3 11 2 — 0 2 5 7 — 0 0 — —
S. Atlantic 21 36 143 2,016 837 5 12 28 346 333 19 58 218 1,293 1,609
Delaware — 0 3 21 11 — 0 2 — — — 0 3 3 17
District of Columbia — 0 4 20 16 — 0 2 7 3 — 2 8 58 91
Florida 9 18 89 956 497 3 3 18 127 126 1 19 31 442 557
Georgia 1 10 28 319 236 1 4 12 92 76 — 14 167 250 337
Maryland§ 3 0 25 277 4 1 1 6 34 52 7 6 12 139 132
North Carolina — 0 0 — — — 0 0 — — — 9 31 200 264
South Carolina§ 8 0 25 317 — — 1 4 35 31 1 2 6 63 63
Virginia§ — 0 4 39 — — 1 4 37 30 10 4 22 135 144
West Virginia — 1 21 67 73 — 0 4 14 15 — 0 2 3 4
E.S. Central 4 12 50 769 188 1 2 8 75 80 6 20 39 432 566
Alabama§ — 0 0 — — — 0 0 — — — 6 17 113 232
Kentucky — 2 16 109 52 — 0 2 9 7 5 2 13 66 26
Mississippi — 1 6 38 31 — 0 2 8 12 — 5 17 94 95
Tennessee§ 4 8 44 622 105 1 2 7 58 61 1 7 16 159 213
W.S. Central 12 7 89 1,109 73 2 6 41 177 207 12 41 72 731 1,398
Arkansas§ 4 2 9 105 34 — 0 3 10 26 10 4 14 75 98
Louisiana — 1 8 47 39 — 0 3 16 17 — 6 27 64 407
Oklahoma 1 0 5 32 — 1 1 5 32 33 2 1 6 33 46
Texas§ 7 0 82 925 — 1 3 34 119 131 — 27 46 559 847
Mountain 6 5 83 1,124 74 1 5 12 156 190 1 8 18 175 272
Arizona 2 0 52 539 — — 2 7 71 84 — 3 10 59 130
Colorado 4 0 20 320 — 1 1 4 41 28 — 2 5 54 46
Idaho§ — 0 1 8 — — 0 1 4 6 — 0 1 2 3
Montana§ — 0 2 13 — — 0 1 1 — — 0 1 — —
Nevada§ — 1 4 46 28 — 0 1 4 6 1 1 10 42 53
New Mexico§ — 0 8 96 — — 0 4 13 23 — 1 4 13 24
Utah — 2 9 94 37 — 1 4 20 42 — 0 2 5 15
Wyoming§ — 0 1 8 9 — 0 1 2 1 — 0 1 — 1
Pacific — 1 14 179 2 — 0 7 24 19 5 38 62 944 1,083
Alaska — 0 9 68 — — 0 5 16 11 — 0 0 — —
California — 0 12 111 — — 0 2 8 — 4 35 57 847 963
Hawaii — 0 1 — 2 — 0 1 — 8 — 0 3 18 19
Oregon — 0 0 — — — 0 0 — — — 0 5 6 29
Washington — 0 0 — — — 0 0 — — 1 3 7 73 72
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 3 17 104 109
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Includes drug resistant and susceptible cases of invasive Streptococcus pneumoniae disease among children <5 years and among all ages. Case definition: Isolation of S. pneumoniae from 
a normally sterile body site (e.g., blood or cerebrospinal fluid).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 3, 2010, and July 4, 2009 (26th week)*
West Nile virus disease†
Reporting area
Varicella (chickenpox)§ Neuroinvasive Nonneuroinvasive¶
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 63 330 535 8,405 13,665 — 0 46 1 23 — 0 49 3 18
New England 2 17 36 383 617 — 0 0 — — — 0 0 — —
Connecticut 2 7 20 176 296 — 0 0 — — — 0 0 — —
Maine§ — 4 15 107 107 — 0 0 — — — 0 0 — —
Massachusetts — 0 1 — 3 — 0 0 — — — 0 0 — —
New Hampshire — 3 8 72 125 — 0 0 — — — 0 0 — —
Rhode Island§ — 1 12 16 22 — 0 0 — — — 0 0 — —
Vermont§ — 1 10 12 64 — 0 0 — — — 0 0 — —
Mid. Atlantic 6 33 66 919 1,289 — 0 2 — — — 0 1 — —
New Jersey — 9 30 340 269 — 0 1 — — — 0 0 — —
New York (Upstate) N 0 0 N N — 0 1 — — — 0 1 — —
New York City — 0 0 — — — 0 1 — — — 0 0 — —
Pennsylvania 6 22 52 579 1,020 — 0 0 — — — 0 0 — —
E.N. Central 19 108 176 2,957 4,298 — 0 4 — — — 0 3 — —
Illinois 1 26 49 738 1,007 — 0 3 — — — 0 0 — —
Indiana§ 9 5 35 274 313 — 0 1 — — — 0 1 — —
Michigan 3 35 62 942 1,263 — 0 1 — — — 0 0 — —
Ohio 6 28 56 820 1,335 — 0 0 — — — 0 2 — —
Wisconsin — 7 24 183 380 — 0 1 — — — 0 0 — —
W.N. Central 7 13 40 334 890 — 0 5 — 2 — 0 11 1 6
Iowa N 0 0 N N — 0 0 — — — 0 1 — —
Kansas§ — 4 18 97 376 — 0 1 — — — 0 2 — 1
Minnesota — 0 0 — — — 0 1 — — — 0 1 — 1
Missouri 7 6 16 199 425 — 0 2 — 1 — 0 1 — —
Nebraska§ N 0 0 N N — 0 2 — — — 0 6 — 2
North Dakota — 0 26 29 54 — 0 0 — — — 0 1 1 —
South Dakota — 0 7 9 35 — 0 3 — 1 — 0 2 — 2
S. Atlantic 6 36 101 1,267 1,669 — 0 4 — — — 0 2 2 —
Delaware§ — 0 6 27 7 — 0 0 — — — 0 0 — —
District of Columbia — 0 4 13 21 — 0 1 — — — 0 0 — —
Florida§ — 15 57 639 854 — 0 1 — — — 0 1 — —
Georgia N 0 0 N N — 0 1 — — — 0 1 2 —
Maryland§ N 0 0 N N — 0 0 — — — 0 1 — —
North Carolina N 0 0 N N — 0 0 — — — 0 0 — —
South Carolina§ — 0 34 72 91 — 0 2 — — — 0 0 — —
Virginia§ 3 11 34 265 448 — 0 2 — — — 0 0 — —
West Virginia 3 8 26 251 248 — 0 0 — — — 0 0 — —
E.S. Central 2 6 28 175 351 — 0 6 1 3 — 0 4 — 1
Alabama§ 2 6 27 173 348 — 0 0 — — — 0 0 — —
Kentucky N 0 0 N N — 0 1 — 1 — 0 0 — —
Mississippi — 0 1 2 3 — 0 5 1 1 — 0 4 — 1
Tennessee§ N 0 0 N N — 0 2 — 1 — 0 1 — —
W.S. Central 21 66 285 1,723 3,245 — 0 19 — 7 — 0 6 — 1
Arkansas§ — 3 32 106 313 — 0 1 — 2 — 0 0 — —
Louisiana — 2 10 64 73 — 0 2 — 2 — 0 4 — —
Oklahoma N 0 0 N N — 0 2 — — — 0 2 — —
Texas§ 21 56 272 1,553 2,859 — 0 16 — 3 — 0 4 — 1
Mountain — 25 48 628 1,231 — 0 12 — 7 — 0 17 — 9
Arizona — 0 0 — — — 0 4 — 3 — 0 2 — 1
Colorado§ — 10 41 239 662 — 0 7 — — — 0 14 — 2
Idaho§ N 0 0 N N — 0 3 — 1 — 0 5 — 1
Montana§ — 3 17 129 108 — 0 1 — — — 0 1 — —
Nevada§ N 0 0 N N — 0 2 — 3 — 0 1 — 3
New Mexico§ — 1 7 59 86 — 0 2 — — — 0 1 — —
Utah — 6 22 188 375 — 0 1 — — — 0 0 — 1
Wyoming§ — 0 3 13 — — 0 1 — — — 0 2 — 1
Pacific — 0 5 19 75 — 0 12 — 4 — 0 12 — 1
Alaska — 0 4 19 45 — 0 0 — — — 0 0 — —
California — 0 0 — — — 0 8 — 4 — 0 6 — 1
Hawaii — 0 2 — 30 — 0 0 — — — 0 0 — —
Oregon N 0 0 N N — 0 1 — — — 0 4 — —
Washington N 0 0 N N — 0 6 — — — 0 3 — —
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 3 9 14 — 0 0 — — — 0 0 — —
Puerto Rico 4 5 30 146 328 — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California 
serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
¶ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
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TABLE III. Deaths in 122 U.S. cities,* week ending July 3, 2010 (26th week)
Reporting area
All causes, by age (years)
P&I† 
Total Reporting area




Ages ≥65 45–64 25–44 1–24 <1
All  
Ages ≥65 45–64 25–44 1–24 <1
New England 453 284 122 26 5 16 33 S. Atlantic 1,129 697 302 76 38 15 61
Boston, MA 120 64 42 5 3 6 9 Atlanta, GA 148 83 36 16 11 2 11
Bridgeport, CT 38 25 8 3 1 1 3 Baltimore, MD 150 85 47 10 6 2 10
Cambridge, MA 13 10 2 1 — — 2 Charlotte, NC 97 67 21 6 3 — 8
Fall River, MA 17 12 4 1 — — 2 Jacksonville, FL 151 98 40 8 3 2 8
Hartford, CT 46 29 10 2 — 5 2 Miami, FL 106 75 20 9 1 — 2
Lowell, MA 14 10 2 2 — — — Norfolk, VA 39 23 13 2 — 1 —
Lynn, MA 8 5 2 1 — — — Richmond, VA 61 38 19 3 — 1 4
New Bedford, MA 16 12 3 1 — — 1 Savannah, GA 47 31 13 1 1 1 2
New Haven, CT 18 14 3 1 — — — St. Petersburg, FL 38 20 11 6 1 — 3
Providence, RI 55 37 12 3 1 2 1 Tampa, FL 185 118 50 9 6 2 4
Somerville, MA U U U U U U U Washington, D.C. 90 48 28 4 6 4 9
Springfield, MA 33 20 8 3 — 2 3 Wilmington, DE 17 11 4 2 — — —
Waterbury, CT 23 16 6 1 — — 2 E.S. Central 953 609 250 56 14 24 87
Worcester, MA 52 30 20 2 — — 8 Birmingham, AL 183 115 53 8 3 4 22
Mid. Atlantic 1,615 1,079 372 93 42 29 75 Chattanooga, TN 86 55 23 6 2 — 7
Albany, NY 43 26 9 2 5 1 2 Knoxville, TN 108 66 31 10 — 1 7
Allentown, PA 31 27 1 2 1 — 3 Lexington, KY 69 42 17 5 — 5 5
Buffalo, NY 73 54 10 4 2 3 4 Memphis, TN 189 115 52 13 5 4 23
Camden, NJ 6 5 1 — — — — Mobile, AL 102 72 24 4 1 1 6
Elizabeth, NJ 20 12 6 1 1 — 1 Montgomery, AL 68 51 12 3 1 1 11
Erie, PA U U U U U U U Nashville, TN 148 93 38 7 2 8 6
Jersey City, NJ 20 12 7 — 1 — 1 W.S. Central 974 621 230 62 33 28 47
New York City, NY 958 652 215 50 21 20 43 Austin, TX 82 45 21 5 4 7 1
Newark, NJ 32 14 10 6 2 — 2 Baton Rouge, LA 62 43 7 9 2 1 —
Paterson, NJ U U U U U U U Corpus Christi, TX U U U U U U U
Philadelphia, PA 145 89 43 7 3 3 6 Dallas, TX 185 109 47 18 7 4 9
Pittsburgh, PA§ 23 17 6 — — — — El Paso, TX 79 53 15 7 2 2 1
Reading, PA 32 25 3 4 — — 2 Fort Worth, TX U U U U U U U
Rochester, NY 72 45 18 5 3 1 3 Houston, TX 159 98 42 4 5 10 9
Schenectady, NY 26 17 7 1 1 — 1 Little Rock, AR U U U U U U U
Scranton, PA 24 18 3 2 — 1 2 New Orleans, LA U U U U U U U
Syracuse, NY 51 28 19 3 1 — 1 San Antonio, TX 259 168 67 15 7 2 16
Trenton, NJ 32 19 9 3 1 — 1 Shreveport, LA 49 31 15 1 — 2 3
Utica, NY 8 6 1 1 — — 2 Tulsa, OK 99 74 16 3 6 — 8
Yonkers, NY 19 13 4 2 — — 1 Mountain 1,052 690 241 76 25 18 73
E.N. Central 1,728 1,104 435 110 44 35 118 Albuquerque, NM 113 72 28 7 2 4 9
Akron, OH 3 3 — — — — 3 Boise, ID 42 29 7 5 1 — 4
Canton, OH 28 16 8 2 1 1 2 Colorado Springs, CO 73 55 13 4 — 1 1
Chicago, IL 234 134 67 23 9 1 15 Denver, CO 65 45 13 3 2 2 4
Cincinnati, OH 91 56 24 7 2 2 10 Las Vegas, NV 261 168 75 13 3 — 21
Cleveland, OH 187 120 50 8 2 7 8 Ogden, UT 36 29 2 — 5 — 4
Columbus, OH 136 79 36 10 5 6 14 Phoenix, AZ 171 108 42 12 4 5 10
Dayton, OH 150 102 31 10 7 — 19 Pueblo, CO 21 12 6 3 — — 2
Detroit, MI 115 64 37 7 5 2 2 Salt Lake City, UT 129 80 23 16 5 5 8
Evansville, IN 37 26 10 1 — — 2 Tucson, AZ 141 92 32 13 3 1 10
Fort Wayne, IN 60 40 17 3 — — 6 Pacific 1,431 981 310 86 27 27 124
Gary, IN 16 9 5 2 — — 2 Berkeley, CA 14 7 5 2 — — 1
Grand Rapids, MI 55 42 7 1 1 4 2 Fresno, CA 131 87 32 7 3 2 17
Indianapolis, IN 200 120 51 15 8 6 15 Glendale, CA 32 29 2 1 — — 6
Lansing, MI 38 29 6 2 1 — 1 Honolulu, HI 62 48 8 2 3 1 9
Milwaukee, WI 50 29 18 3 — — 3 Long Beach, CA 67 40 23 4 — — 6
Peoria, IL 47 36 8 1 1 1 4 Los Angeles, CA 254 163 56 23 7 5 19
Rockford, IL 53 33 12 4 1 3 2 Pasadena, CA 15 11 4 — — — 1
South Bend, IN 56 39 10 6 — 1 2 Portland, OR 99 71 20 3 — 5 4
Toledo, OH 91 65 23 3 — — 3 Sacramento, CA 175 114 41 16 4 — 16
Youngstown, OH 81 62 15 2 1 1 3 San Diego, CA 147 112 26 5 2 2 11
W.N. Central 819 529 195 42 23 29 48 San Francisco, CA 97 66 19 5 3 4 11
Des Moines, IA 150 104 28 8 5 5 7 San Jose, CA 174 125 37 7 2 3 12
Duluth, MN 25 16 9 — — — 2 Santa Cruz, CA 29 19 9 — — 1 1
Kansas City, KS 30 18 10 2 — — 3 Seattle, WA 85 57 18 7 1 2 8
Kansas City, MO 93 59 23 5 3 2 2 Spokane, WA 50 32 10 4 2 2 3
Lincoln, NE 59 45 8 3 1 2 7 Tacoma, WA U U U U U U U
Minneapolis, MN 61 37 15 7 1 1 3 Total¶ 10,154 6,594 2,457 627 251 221 667
Omaha, NE 86 55 21 2 2 6 4
St. Louis, MO 197 116 54 10 7 10 12
St. Paul, MN 42 29 9 2 2 — 4
Wichita, KS 76 50 18 3 2 3 4
U: Unavailable.   —: No reported cases.   
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and 
by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¶ Total includes unknown ages.
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